Fluorescence molecular tomography: Principles and potential for pharmaceutical research by Stuker, F et al.
Pharmaceutics 2011, 3, 229-274; doi:10.3390/pharmaceutics3020229
OPEN ACCESS
pharmaceutics
ISSN 1999-4923
www.mdpi.com/journal/pharmaceutics
Review
Fluorescence Molecular Tomography: Principles and
Potential for Pharmaceutical Research
Florian Stuker 1, Jorge Ripoll 2,∗ and Markus Rudin 1,3,∗
1 Institute for Biomedical Engineering, University and ETH Zurich, Wolfgang-Pauli-Strasse 10,
8093 Zurich, Switzerland
2 Institute of Electronic Structure and Laser - FORTH, Vassilika Vouton, 71110 Heraklion,
Greece
3 Institute of Pharmacology and Toxicology, University Zurich, Winterthurerstrasse 190, 8057
Zurich, Switzerland
? Authors to whom correspondence should be addressed;
E-Mail: jripoll@iesl.forth.gr (J.R.); Tel.: +30 2810 391922 (J.R.); Fax: +30 2810 391305 (J.R.);
E-Mail: rudin@biomed.ee.ethz.ch (M.R.); Tel.: +41 44 6337604 (M.R.); Fax: +41 44 6331187
(M.R.).
Received: 6 February 2011; in revised form: 7 April 2011 / Accepted: 15 April 2011 /
Published: 26 April 2011
Abstract: Fluorescence microscopic imaging is widely used in biomedical research
to study molecular and cellular processes in cell culture or tissue samples. This
is motivated by the high inherent sensitivity of fluorescence techniques, the spatial
resolution that compares favorably with cellular dimensions, the stability of the
fluorescent labels used and the sophisticated labeling strategies that have been
developed for selectively labeling target molecules. More recently, two and
three-dimensional optical imaging methods have also been applied to monitor biological
processes in intact biological organisms such as animals or even humans. These whole
body optical imaging approaches have to cope with the fact that biological tissue is
a highly scattering and absorbing medium. As a consequence, light propagation in
tissue is well described by a diffusion approximation and accurate reconstruction of
spatial information is demanding. While in vivo optical imaging is a highly sensitive
method, the signal is strongly surface weighted, i.e., the signal detected from the same
light source will become weaker the deeper it is embedded in tissue, and strongly
depends on the optical properties of the surrounding tissue. Derivation of quantitative
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information, therefore, requires tomographic techniques such as fluorescence molecular
tomography (FMT), which maps the three-dimensional distribution of a fluorescent
probe or protein concentration. The combination of FMT with a structural imaging
method such as X-ray computed tomography (CT) or Magnetic Resonance Imaging
(MRI) will allow mapping molecular information on a high definition anatomical
reference and enable the use of prior information on tissue’s optical properties to
enhance both resolution and sensitivity. Today many of the fluorescent assays
originally developed for studies in cellular systems have been successfully translated for
experimental studies in animals. The opportunity of monitoring molecular processes
non-invasively in the intact organism is highly attractive from a diagnostic point
of view but even more so for the drug developer, who can use the techniques for
proof-of-mechanism and proof-of-efficacy studies. This review shall elucidate the
current status and potential of fluorescence tomography including recent advances in
multimodality imaging approaches for preclinical and clinical drug development.
Keywords: fluorescence molecular tomography; biomedical imaging; optical
tomography; fluorescence; hybrid imaging
1. Fluorescence Imaging as Tool to Study Molecular Processes
Optical imaging and in particular fluorescence imaging is nowadays widely used for preclinical
molecular imaging due to a number of reasons. Optical imaging techniques are sensitive and
therefore well suited to detect low concentration of target molecules in tissue. Optical reporter
systems such as fluorescent dyes or bioluminescence or fluorescent reporter proteins are stable
molecules and can be easily targeted to report on specific molecular processes in vivo. Thus
optical imaging can build on a wealth of tools that have been developed for optical microscopy.
Additionally, the techniques are relatively inexpensive, which facilitates their protrusion into the
biomedical research community.
Optical imaging in small animals was originally confined to qualitative or semi-quantitative two
dimensional imaging of light distribution on the surface of the specimen, what we shall term here
“planar imaging”. The experimental setup for such measurements is simple and consists of wide
field illumination for excitation (in the case of fluorescence imaging) and a highly sensitive detector
for capturing the fluorescence signals using appropriate filters. Proper quantification is prevented
by the fact that light transport in tissue is non-linear, hence the fluorescence intensity measured
at the surface cannot be unambiguously assigned to a distribution of fluorescent molecules within
the object. For example, it is not possible from a single measurement of light distribution on the
surface of a turbid sample to discriminate a focalized, deeply embedded, highly concentrated probe
from a disperse weak probe located close to the surface. In order to derive quantitative information
from optical imaging data set, two criteria have to be fulfilled: (1) Light transport in tissue has to
be accurately accounted for, which requires a theoretical model and adequate knowledge of optical
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parameters of tissue (absorption and scattering coefficients) and (2) most importantly sufficient
number of independent experimental data has to be gathered to allow extracting the unknown
distribution of reporter probe within tissue. Progress in understanding and developing models for
describing the light/tissue interaction allowed constructing a framework towards three-dimensional
quantitative fluorescence tomography.
The number of independent data samples is given by the number of light sources (the
different position of the light source tightly focused on the surface) and the number of detector
used (source-detector pairs) for each measured excitation/emission set. In the planar imaging
mode, wide field illumination would correspond to an infinite number of point sources used
simultaneously; yet it is mathematically not possible to deconvolve the contribution of individual
sources, preventing reconstruction of the three-dimensional probe distribution. By replacing wide
field illumination by a sequential scan of focal light sources, it is possible to measure each individual
source detector-pairs at the expense of a prolonged measurement time. This is the basic principle
of fluorescence molecular tomography (FMT) [1,2]. Correspondingly, the imaging equipment used
for FMT comprises a sensitive (array) detector and a narrow excitation beam, which is scanned
point by point over the region of interest using a scanning device. While the first systems described
were liquid based and the sample had to be forced into a regular geometrical configuration of an
index-matching fluid filled cylinder or a parallel chamber, advances in the theoretical framework
and in modeling capacities led to the introduction of so-called non-contact (free space) scanners
capable of handling data acquired from arbitrarily shaped objects without the need of matching
fluid. Due to difficulties in experimental handling of liquid based systems and the non-natural
upright positioning of the animal, non-contact systems allowing horizontal sample positions are
more convenient. Nevertheless, liquid based setups offer high sensitivity and high signal-to-noise
ratios compared to modern non-contact systems.
Today, FMT provides similar molecular and functional information as radionuclide based
positron emission tomography (PET); both modalities suffer from relatively poor spatial resolution
in comparison to structural/anatomical imaging modalities such as X-ray computed tomography
(CT) and magnetic resonance imaging (MRI), which may render allocation of molecular data to a
specific anatomical structure difficult. Another concern related to FMT is the limited penetration
depth of light into tissue, which ranges from a few millimeters for wavelengths shorter than
500 nm (green, blue) to several centimeters for wavelengths longer than 650 nm (red, near-infrared).
Therefore, FMT is mainly used in combination with probes absorbing and fluorescing in the red to
near infrared (NIR) spectral range, for which the light penetration depth is sufficient for pre-clinical
imaging using small animals and even humans.
An attractive possibility to account for limited spatial resolution is to combine low resolution
molecular imaging techniques (PET or FMT) with CT or MRI, enabling the annotation of
anatomical structures with molecular information. In addition, structural information may be
used to better confine the reconstruction problem for the low resolution technique. In the case
of FMT, structural information together with optical parameters for specific tissues may be
incorporated into the forward problem as a priori information, which is either acquired sequentially
or simultaneously, the latter requiring hybrid imaging instrumentation. Hybrid FMT techniques
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will become increasingly important in pre-clinical applications as it provides complementary
readout of improved quality.
FMT and related techniques such as diffuse optical tomography (DOT), which measure intrinsic
tissue properties related to the principal absorbers hemoglobin and deoxyhemoglobin [3], are
non-invasive and essentially translatable into the clinics. Established applications of DOT
comprise breast imaging, neonatal brain imaging and examination of finger joint in osteoarthritis,
amongst others. DOT systems for breast imaging in clinics are even commercially available
(ART Advanced Research Technologies Inc., CA and Imaging Diagnostic Systems Inc., US).
However, clinical application of FMT is currently hampered by the fact that there are hardly
any fluorescent dyes approved for clinical use. As an example, only indocyanine green (ICG) for
studies in female breast [4,5] and fluorescein used in ophthalmology [6] have been reported but
these fluorescent probes are unspecific, yielding information only on vasculature with very high
background fluorescence.
This review focuses on the development of FMT and related technologies and their potential
applications in biomedical research and drug discovery. We will briefly discuss the theoretical
foundation underlying light propagation in tissue, which is relevant for FMT. Then the
development of FMT will be reviewed, with a particular focus on recent technical developments
towards hybrid imaging systems. Representative applications of optical imaging in pharmaceutical
research illustrating the potential but also the limitations of the approach will be discussed.
2. In vivo Fluorescence Imaging
Reconstructing the three-dimensional distribution of optical parameters (tissue absorption
coefficient, scattering coefficient, fluorophore distribution) comprises three steps: (i) A model
of light transport in tissue has to be developed. This model comprises a structural model of the
sample itself, which in the simplest approximation consists of a single homogeneous compartment
characterized by one set of optical parameters. More realistic tissue models are based on the
actual anatomy with different optical parameters for each organ/tissue. (ii) The model is then
used to compute the propagation of light emanating from a specific source location throughout
the object examined. This so-called forward problem allows estimating the intensity distribution
at the sample surface (simulated measurements). For each source location a different surface
intensity pattern is obtained. It yields the sensitivity matrix (Jacobian- or weight-matrix), which
relates the measurements at the surface to the internal optical properties of the sample. Each
element of the sensitivity matrix corresponds to a specific source-detector pair. (iii) The unknown
three-dimensional distribution of optical parameters is then estimated from the measurements
recorded for the different source locations, the so-called inverse problem. It formally corresponds
to inverting the sensitivity matrix. Since scattering dominates light propagation in tissue,
light diffuses almost isotropically through the entire sample volume. Each detector element
therefore collects information from the whole volume, which renders deconvolution difficult.
Typically this ill-posed, under-determined inverse problem cannot be solved analytically but
rather by inverting an under-determined matrix through regularization or iterative methods, both
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being computationally intense. In the following we will outline the most relevant aspects of
reconstructing three-dimensional optical data sets.
2.1. Light Propagation in Turbid Media
Tissue is a highly scattering medium in which light propagates qualitatively as it does in
milk. Light propagation in tissue is governed by scattering and absorption events characterized
by scattering and absorption coefficient, which depend on the specific tissue type and on the
wavelength of the light. The main absorbers in biological tissue are blood in the visual domain of
the spectrum and water in the infrared domain. For example, the absorption coefficient of high
blood content organs such as the liver, spleen and heart is very high for wavelengths λ < 600 nm.
During light propagation in tissue light is multiple times deflected from its original direction, with
the result that after a short distance (typically 1 mm) light propagates on average in all directions
in space (isotropic scattering) leading to a rapid decrease in light intensity with increasing distance
from the light source, following the diffusion approximation. Therefore light propagation in tissue
cannot be described using a straight ray geometry (Figure 1a) but rather as the migration of an
ensemble of light paths that are randomly scattered (Figure 1b). This is achieved by the linear
transport theory in turbid medium: conservation of radiance L(r, s, t) [W m−2 sr−1 s−1], which is
the amount of light that passes through a particular area at position r in a specific direction s
within a solid angle dΩ, is described by the so-called radiative transport equation (RTE) [7]. The
RTE can be written as
1
υ
∂L(r, s, t)
∂t
+ s · ∇L(r, s, t) + µtL(r, s, t) = µs
∫
4pi
L(r, s′, t)p(s, s′)dΩ ′ + S(r, s, t) (1)
where υ is the speed of light in the medium, µt = µa + µs is the total attenuation coefficient
accounting for absorption and scattering and p(s, s′) is the normalized scattering phase function
which predicts how light incoming from direction s′ is deflected towards direction s. The left hand
side of Equation (1) describes the effects reducing the total radiance in a certain point r in space
in a specific direction s and the right hand side accounts for the increasing effects.
Solutions of Equation (1) are computationally expensive even for simple conditions/geometries.
Therefore for practical applications the diffusion approximation (DA) to the RTE is used providing
the advantage of its relative mathematical simplicity. The DA assumes that all contributions to
light transport within the medium are from multiple-scattered light and thus the intensity can
be considered as diffuse. Furthermore, the DA involves the expansion of the key parameters into
spherical harmonics [8] maintaining the linear terms only. The diffusion equation describing light
propagation in tissue can be read for a homogeneous medium as
1
υ
∂
∂t
U(r, t)−D∇2U(r, t) + µaU(r, t) = S(r, t) (2)
U(r, t) is the average intensity [W cm−2 s−1] and D = 1/3(µa + µ′s) the diffusion coefficient [cm]
with the reduced scattering coefficient µ′s = µs(1−g), g accounting for the anisotropy of scattering
(it represents the average cosine of the scattering angle). Note that the radiance has been replaced
by the average intensity, i.e. in Equation (2) the quantity that obeys the diffusion equation is the
average intensity or equivalent, the energy density (U/υ).
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However, one should realize that the assumptions involved start to deviate in distances in
the order of the mean free path lsc from light sources or non-diffusive regions to mention the
most relevant constraints. The mean free path is defined as lsc = 1/µs characterizing the
distance between two scattering events. For such cases higher order approximations to the RTE
are required.
Figure 1. Light propagation in tissue: (a), Highly absorbing medium where the mean
free path lsc defining the distance between two scattering events is large compared to
1/µs, µs being the scattering coefficient. In this case the light intensity decreases with
the distance d according to I ∝ I0exp(−µtd) where µt = µs+µa. (b), Highly scattering
medium where lsc is approximately 1/µs. This case represents the situation in tissue
where light propagation can be modeled with diffusion theory.
a b
1/μs << lsc 1/μs ~ lsc
2.2. Forward Problem
The forward problem aims at solving the diffusion equation Equation (2) for a specific sample
geometry. First concerns about a theory breakdown for sources and detectors separation of less
than a few mean free path length [9] was later abolished by showing that even smaller separation
can provide good results [10]. For a fluorescent sample embedded in tissue the fluorescence average
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intensity Ufl excited with an appropriate continuous wave (CW) source located at rs and detected
by the detector at position rd can be described by a volume integral [11,12]
Ufl (rs, rd) =
∫
V
d3r Qinstr
1
Dλexc
Gλexc(r, rs)
n(r)
Dλfl
Gλfl(rd, r) (3)
where Qinstr is a scaling factor accounting for specific parameters of the instrumentation used, Dλfl
and Dλexc are the diffusion coefficients at fluorescence and excitation wavelength, respectively,
n(r) is the unknown spatial distribution of fluorochrome concentration. The Green’s functions
Gλexc(r, rs) and Gλfl(rd, r) describe the propagation of light from the point source to a point
within the fluorochrome and from a point within the fluorochrome to a point on the detector,
respectively (note that in this formula sources and detectors are considered delta functions: if
dimensions of these wish to be included, Equation (3) needs to include an integral on the detector
and source areas). These functions are related to the structural geometry of the model and there
exists different approaches to derive the Green’s functions: Analytical solutions only exist for
simple geometries such as infinite or semi infinite media [13], slabs [14,15], layered slabs [16,17],
parallelepiped [18], cylinder [19], layered cylinders [20] spherical perturbations [21] a summary of
solutions for different geometries can also be found in [22]. Although the range of solutions was
extended to arbitrary complex shaped geometries based on analytical solutions of the diffusion
equation [23]. An aspect to consider, in particular in structured samples, is light propagation
at tissue boundaries. For the discussion of boundary conditions we refer to the literature [13].
Alternative strategies to solve Equation (2) have been used, such as Monte Carlo simulations.
A detailed summary and references to forward modeling techniques are given in the review of
Gibson et al. [24].
The use of the linearized Equation (3) is difficult since the instrumental parameter Qinstr has to
be explicitly determined. To overcome this issue Ntziachristos et al. [25] developed the concept of
normalized measurements, which is based on the ratio of intensities measured at the fluorescence
wavelength divided by those measured at the excitation wavelength. The authors demonstrated
its feasibility even within the Born approximation, what the authors termed normalized Born
approximation. Assuming Qinstr to be largely wavelength independent, this normalized ratio
becomes independent of any instrumental pecularities and was shown to yield robust and accurate
data for the distribution of a fluorophore in heterogeneous media [26,27].
The excitation field can be modeled as follows [12]
Uexc(rs, rd) = Qinstr
1
Dλexc
Gλexc(rd, rs) (4)
yielding for the normalized average intensity Un
Un(rs, rd) =
Ufl(rs, rd)
Uexc(rs, rd)
= 1
Dλfl
∫
V d
3r Gλexc(r, rs)n(r)Gλfl(r, rs)
Gλexc(rd, rs)
(5)
For reconstruction purposes Equation (5) can be discretized into N volume elements also known as
voxels replacing the integration by a summation, which is the Born approximation. For multiple
source detector pairs a set of linear equations arises and the forward problem can be written in a
matrix form
UM×1 = WM×N · nN×1 (6)
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where UM×1 is the measurement vector, W weight matrix of the dimension M × N where M is
the number of measurements and N is the number of Voxels and nN×1 is the unknown fluorophore
concentration distribution in each voxel.
2.3. Inverse Problem
Direct inversion of Equation (6) to solve for the unknown parameter n is not possible due
to the ill-posed (violation of at least one of the properties defined by Hadamard for well-posed
problems: A solution exists, the solution is unique and the solution continuously depends on the
data), ill-conditioned (a small error in U may cause a large error in n) and underdetermined (more
unknowns than equations) nature of the problem. Standard linear reconstruction techniques such
as algebraic methods can be used to solve the problem. Among those the algebraic reconstruction
technique (ART) and the simultaneous iterative reconstruction technique (SIRT) [28] are the
most common ones. Recently other strategies such as regularization methods (e.g., Tikhonov
regularization) for data reconstruction have been proposed which under certain conditions have
yielded superior results as compared to ART [29].
Different strategies to solve the inverse problem are iterative procedures: An estimate of the
fluorochrome distribution can be found by least-square minimization of the difference between the
measured average intensity U and the intensity predicted by the forward model Uˆ . A detailed
description of solution techniques for the inverse problem is beyond the scope of this review article
and the interested reader is referred to the literature [8,30].
2.4. Fluorescence Probes
Target specific probes that report on cellular and molecular processes in the living organism are
the key to molecular imaging. There are two strategies for probe design: exogenous synthetic and
genetically encoded reporter systems. The design of exogenous probe comprise a targeting moiety
(e.g., a receptor binding ligand) and a reporter moiety that will generate a signal detected by the
respective imaging modality. It is important that the reporter group has no or only a minimal
effect on the target interaction of the probe, i.e., it should not interfere with the pharmacophor of
the targeting moiety responsible for the receptor binding. Molecular targets typically occur at low
concentration increasing the demands on the sensitivity of the reporter principle. Optical and in
particular fluorescence techniques provide excellent sensitivity and are therefore highly attractive
for such applications.
Optical reporters can be divided into three main groups: small synthetic, organic dyes such as
cyanine-, oxazine-compounds, genetically encoded fluorescent proteins such as green fluorescent
protein (GFP) and semiconductor solid-state nanoparticles such as quantum dots. Dye molecules
and fluorescent proteins contain a structure with delocalized pi-electrons, the dimension of which
determines the absorption/excitation spectrum. As a rule of thumb we may state that the longer
the pi-system the more red-shifted the spectrum. This property has been used for the design of red
and NIR dyes as well as for the genetical engineering of red-shifted fluorescent proteins [31,32].
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Quantum dots display a broad excitation but a narrow emission spectrum, the central frequency
of which depends on the physical dimension of the quantum dot (as long it does not exceed the Bohr
radius of the electron-hole pair). As a consequence different quantum dots can be excited with a
single excitation wavelength, a property that lends itself for multiplexing studies, i.e., simultaneous
probing of multiple processes. The drawback of this class of probes is the challenging spectral
unmixing procedure to assign the different fluorescent wavelength to the studied multiple processes.
Another interesting class of nanoparticles are phosphor nanoparticles consisting of a crystalline
matrix doped with lanthanide ions. They display lower toxicity than quantum dots and offer
the possibility of upconversion, which means that emission is observed at a shorter wavelength
(i.e., corresponding to a higher energy difference) than the excitation wavelength. The main
advantage of these probes is the complete removal of autofluorescence and therefore better imaging
performance. The mechanism underlying upconversion is based on multiple photon absorption
and shows advantages of sharp emission lines, long lifetimes and superior photostability [33–
35]. Phosphor nanoparticles have also been used for X-ray luminescence computed tomography
(XLCT) [36,37] which is based on the conversion of X-ray into visible light.
Figure 2. In vivo planar imaging of an activatable probe. (a), In vivo NIR fluorescence
imaging of HT1080 tumor-bearing animals. The top row shows raw image acquisition
obtained at 700 nm emission. Untreated (left), treated with 150 mg/kg prinomastat,
twice a day, i.p. for 2 d (right). The bottom row shows color-coded tumoral
maps of MMP-2 activity superimposed onto white-light images (no treatment (left),
prinomastat treatment (right)). (b), Quantitative image analysis of all 20 tumors.
Tumoral NIR fluorescence signals are shown in a box plot (bars indicate 10th and 90th
percentile). The difference in imaging signal between the two groups was statistically
significant (P < 0.0001) (Adapted from [38]; reprinted with permission).
a
b
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An attractive feature of fluorescence is that it can be modulated by the environment (this,
of course, if not taken into account also represents an uncontrolled variable in an imaging
experiment). Chemical reactions may modify the structure of the fluorophore and thereby the
absorption/emission spectrum of fluorescent dyes may interact with nearby molecules leading
to fluorescence quenching or resonance energy transfer. These properties have prompted the
development of so-called smart or activatable probes (Figure 2), the fluorescence intensity of which
is altered upon interaction with their molecular target, e.g., switched “on” and “off” when the
dye is interacting with a nearby quenching molecule [39]. Such probe designs are advantageous
since an unbound probe would not give rise to a fluorescence signal, which results in a high
target-to-background ratio (TBR). Similar designs are not feasible for radiotracer probe, which
are always “on”, i.e., the radionuclide decays with a certain probability; correspondingly TBR
may be compromised.
Alternatively, fluorescence light might be generated by bioluminescence. Bioluminescence is
a naturally occurring form of chemiluminescence: A (bio)chemical reaction yields a molecular
product in an excited state that is stabilized by emission of light. This type of assay is widely
applied in biomedical research to visualize molecular processes; in the vast majority of cases
oxidases such as firefly luciferase, which generate light upon oxidation of their substrates, are used
as a reporter systems.
A detailed description of optical probe design and synthesis is beyond the scope of this review
article and the interested reader is referred to the literature [40–43].
3. Non-Invasive Imaging Approaches
3.1. Planar Imaging
The simplest approach for imaging the distribution of a fluorophore in vivo is planar imaging,
also called fluorescence reflectance imaging (FRI). In this case the signal detected is heavily
surface weighted, i.e., is dominated by the contribution of dye molecules at or close to the
surface. The instrumental design is such that large parts of the animal or the whole animal
is simultaneously illuminated, e.g., using an optically expanded laser beam at the excitation
wavelength, light emitting diodes or a white light source using appropriate bandpass filters. The
fluorescent light from the tissue surface is detected using a high sensitive charged-coupled device
(CCD) camera (Figure 3 left column). The noise requirement (e.g., electronic noise which could
potentially influence the imaging performance) of the camera for planar imaging is not as stringent
since in general the detection sensitivity limit is governed by the background tissue fluorescence
(autofluorescence). The use of bandpass filters with high transmission efficiency for a narrow
wavelength range is essential to prevent bleed-through of excitation light into the fluorescent
images. The use of lenses with a low f-number, i.e. large aperture, warrants a high light collection
efficiency. For anatomical registration the fluorescence images are superimposed on mouse images
typically obtained with white light illumination. FRI approaches were first described in 1999 [44]
and then successfully used to study epidermal growth factor receptor (EGFR) labeled with Cy5.5
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in breast tumors [45], tumor protease activity of breast carcinoma [44,46], protease activity in
arthritis [47], osteoblast activity in vertebra [48] and GFP expressing tumors [49] in mice.
Fluorescence intensity measured at the detector depends on the length of the total light
path (excitation and fluorescence light) through tissue. For FRI fluorescent sources close to
the surface contribute much more than deeply embedded ones. In particular autofluorescence
of superficial structures will limit the depth field of view of FRI. In comparison, when using
transillumination, the total path length is approximately constant irrespective of the location
of the fluorescence source within the sample, which enhances the detection probability for
deeply embedded fluorescent sources. Fluorescence transillumination was used in various research
fields [50] and can be considered as an extension of the transillumination approach used in 1929 by
Cutler [51] to resolve absorbing lesions in breast tissue. This method produced shadows attributed
to vascular structure (shadowgrams) and has been further developed for breast imaging.
Normalization fluorescence planar imaging in reflectance and transillumination mode has been
shown to further improve image quality, depth sensitivity and imaging accuracy compared to
non-normalized data [52]. An extension of this imaging approach is the use of spectral information
in the image to discriminate the contributions by different fluorochromes or to reduce the
contribution of tissue autofluorescence (non-specific background fluorescence) [53,54]. Even though
these suggested image improvements makes planar imaging a reliable tool for researchers, it still
suffers from a lack in depth resolution and difficult quantification.
In summary planar optical imaging is attractive for qualitative high-throughput measurements
demonstrating the presence of a fluorescent probe in vivo or in excised tissues. The method
provides no depth resolution and correspondingly difficult quantification of the data. Technical
simplicity and easy handling makes it an attractive screening modality in the biology lab. In
addition planar optical imaging instrumentation is relatively inexpensive.
3.2. Tomography Imaging
In order to reconstruct a three-dimensional data set containing NV = Nx × Ny × Nz voxels
N independent measurements (each corresponding to an individual source detector pair) are
required. As already stated, planar imaging is mathematically equivalent to having a high number
of point sources illuminating simultaneously, which implies that each source-detector pairs cannot
be distinguished (deconvolved) individually. By using sequential illumination of the individual
sources this problem can be circumvented. This is the basic principle of DOT and FMT: Tissue is
sequentially illuminated with an array of light sources and the emanating light is captured with an
array of detectors (Figure 3 right column). For each source location, of a total Ns sources being
sampled, the light distribution on the sample surface is recorded with each detector of the Nd
detector array. A light propagation model for the specific sample is developed and parameterized
in terms of unknown scattering and absorption coefficient as a function of position in the tissue.
By comparing the model prediction with the experimental intensity measurements of all Ns ×Nd
source-detector pairs, optimized values for the distribution of scattering and absorption parameters
are obtained.
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Figure 3. Planar and FMT imaging: (a), Setup. Schematic of a planar (left)
and an FMT (right) measurement setup and its components in reflection geometry.
Transmission geometry (not shown) can be easily achieved by installing either the
camera or the source on the other side of the sample. (b), Schematic of an embedded
fluorophore (turquoise) in depth of a cubic sample (gray). (c), (left) Imaging result
of the planar setup showing the light distribution at the surface of the sample. Only
qualitative information is obtained. (right) Reconstructed fluorophore of an FMT data
set allowing the depth resolution and therefore quantification.
Camera
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Emission lter
Sample
Light source
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mirrors
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The theory was further extended to not only deal with intrinsic contrast but to also account
for fluorescence contrast, termed as fluorescence diffuse optical tomography (fDOT). Fluorescence
measurements can be obtained using appropriate filters in front of the detectors. Similar generic
tomography principles are used for reconstructing the distribution of a fluorescence agent in the
tissue. The use of targeted probes in DOT is what finally granted the access of optical tomography
into the molecular imaging world. This technique was originally termed Fluorescence-mediated
Molecular Tomography, but is currently referred to simply as Fluorescence Molecular Tomography
(FMT) [1]. It represents a novel concept and a complete change of mindset and application targets
when compared with DOT and fDOT, even though the physics behind them is equivalent. The
main goal of FMT is to obtain molecular information on intact biological organisms.
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There exist three basic illumination-detection technology schemes for optical tomography
imaging [55,56]: (a) the continuous wave (CW) domain using light of constant intensity;
(b) the frequency domain (FD) using light of modulated intensity (typically 100 MHz-1 GHz) and
(c) the time-domain (TD) using ultrafast laser pulses (femtosecond to picosecond) [57]. The CW
approach is attractive, as low cost illumination sources can be used and an optimal signal-to-noise
performance is achieved due to the high stability and low noise characteristic of the light sources
and detectors. Nevertheless the major drawback of the method is the difficulty of separating
the contributions of absorption and scattering from the signal attenuation and the inability to
image fluorescence lifetime. Time domain methods resolve the arrival of light from the laser
pulse as a function of time at different positions on the tissue. Information from early arriving
photons can be used to improve resolution since they have suffered less scattering events [58,59].
Highly diffusive and thus delayed photons are rejected. TD methods are less sensitive (they
record a smaller number of photons) and the instrumentation is noisier than CW systems due
to time and intensity fluctuations associated with fast switching electronics and pulsing lasers.
In FD technologies the laser intensity is frequency modulated, which allows the analysis of the
emanating wave with regard to amplitude and phase shift. This allows measuring the tissue
optical properties and the fluorochrome distribution. FD methods are less affected by ambient
light than CW and TD methods. To improve the resolution compared to CW a modulation
of several hundred MHz or higher is required. FD methods are less robust than CW methods
because of the reduced signal-to-noise detection involved in sensing high frequencies. Therefore,
for molecular imaging applications, where the signals are in general weak, CW technologies are
advantageous because of better signal-to-noise performance [55]. This is comparable to DOT,
where mainly endogenous absorption changes (e.g., blood oxygenation changes) and scattering
properties of tissue are measured. For DOT application the imaging systems are based on TD or
FD methods.
One of the first optical tomography scanners was developed for breast imaging in clinics.
The DOT measurement setup worked in TD and was based on a parallel plate geometry [60]
where the breast was slightly compressed and could therefore considered as a homogeneous slab
during reconstruction. Additionally this development was also the first hybrid approach as in
the parallel plates MR coils with fiducial markers were implemented to acquire simultaneous
data sets. The first ICG enhanced breast images were in good correlation with the acquired
contrast agent enhanced MR images in terms of lesion localization [5]. Some years later,
driven by the fast development of fluorescent reporter systems in preclinical research and further
theoretical understandings in the field of light propagation the first FMT scanner based on CW
techniques and designed for cylindrical geometry for preclinical application was reported by
Ntziachristos et al. [2]. Optical fibers were arranged in rings around a cylindrical cavity and
connecting either detectors or light sources with the imaging chamber. The sample is placed
vertically in the chamber, which was filled with a fluid matching the average optical properties of
living tissue. A respectable spatial resolution of 3 mm (resolved gap between two capillary tubes)
and a detection limit of 1nM of Cy5.5 contained in 100µl was found in cylindrical phantoms [2]
and revealed the potential of using optical tomography techniques to detect fluorescent probes in
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small animals which was demonstrated by resolving enzymatic activity in brain tumors in mice [1].
This index matching fluid was on one hand used to increase signal-to-noise ratio and on the other
hand to simplify theoretical constraints associated with boundary modeling: for the reconstruction
the irregular object was assumed having quasi-cylindrical geometry.
Cylindrical fiber based systems using matching liquid based methods suffer from several
limitations. Due to geometrical constraints only a limited number of fibers can be used, reducing
the number of source-detector pairs sampled. Other limitations are light loss due to coupling
between tissue and fibers and restrictions with regard to body regions that can be sampled. It
was shown in simulation analysis of a plane parallel geometry that an increased field of view and
smaller distances between the detector fibers could improve the resolution [61]. Based on this
knowledge a vertical parallel plate imager was developed for clinical breast imaging, where the
breast is suspended in a tank filled with matching fluid and one plate was movable to compress
tissue [4,62]. The source fiber grid was attached on one side of the imaging chamber and the light
was acquired on the other side of the chamber by using a CCD camera focused onto the glass
window using a set of imaging lenses. With that, the fiber-optic detector could be replaced and
the number of detector locations could be enormously increased allowing a higher resolution. This
vertical imaging geometry was then also used for preclinical applications in small animals [63].
These systems offer a higher number of source/detector pairs but still suffer from the limitation of
fixed geometries, tissue compression and matching fluid. Using such a device a superiority of FMT
over FRI could be demonstrated: In a mouse tumor study protease activity in the tumor could
only be accurately visualized in the FMT data [63]. A further modification of a parallel plate
imager was shown by Zacharakis et al. where the plates were horizontally installed and instead of
fiber source illumination a free beam illumination was used in combination with a galvanometric
driven mirror scanner for the point grid scanning [64].
A major conceptual step was the introduction of so-called non-contact excitation/detection
concepts for irregular geometries in FMT, for which there is no geometrical constraint due to
optical fibers and no additional light dispersion due to the use of a fluid filled chamber [65]. This
required the development of a theory for solving the problem of light propagation from diffuse
media (tissue) into free-space (surrounding air) assuming detectors at positions away from the
diffuse medium [66]. Experimental feasibility was demonstrated both in phantom studies [67] and
in vivo [65]. It was successfully shown that a non-contact setup can be built for sample placements
in a more natural horizontal position for lymph nodes [68] and lung tumor [69] imaging instead
of the previously mentioned upright sample positioning setups. All of the so far mentioned setups
have the limitation that due to a fixed positioning only parts of the animal can be imaged.
Therefore a concept based on the rotating gantry principle used in CT was used to image the
animal 360◦. In such systems the sample is placed vertically in a rotating cylinder and can be
transilluminated for 360◦ [70,71]. A further advantage of these systems is the straight forward
implementation of the surface capture by white light projection illumination [72]. Yet another
interesting setup used to image tumor bearing mice was proposed by Li et al. and is based on
a conical mirror design [73]. The sample is place horizontally and is surrounded by the conical
mirror allowing on one hand a sample surface extraction and on the other hand a non-contact
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detection and a free-beam illumination covering the animals surface in a half space. Non-contact
FMT appears today as a fast and powerful technique for preclinical applications, is characterized
by high sensitivity, yet suffers from relatively poor spatial resolution (1 to 2 mm). Resolution is
limited by the physical nature of light propagation in tissue, by the unknown anatomical features
of the sample, by the uncertainty regarding optical parameters of tissue and restricted number of
independent source-detector measurements. The next step would be to use structural information
provided by complementary imaging modalities for better confining the reconstruction problem
in FMT.
3.3. Multimodality Imaging to Derive Multiplexed Information from Biological Systems
In the last decade the role of optics in multimodality imaging or hybrid imaging combining
two or more methods to generate complementary read-outs has become an attractive research
area. Multimodal in vivo imaging systems enable visualization and quantitative assessment of
anatomical, physiological, metabolic and cellular properties of an organism as well as its molecular
constituents and/or pathways by exploiting different mechanisms generating an imaging signal.
Due to economy of scale and technical complexity research today is focused on combining two
individual techniques typically combining structural information with an additional readout.
Examples are the combination of an anatomical method such as CT, MRI or ultrasound scanning
with optical imaging methods providing cellular and molecular insight. Alternatively, optical
imaging could be combined with positron emission tomography (PET) or single photon emission
computer tomography (SPECT) both providing functional and/or molecular information.
Two strategies can be pursued for merging information generated by different imaging
techniques: (1) Measurements can be carried out sequentially using a sample support that is
compatible with several modalities. Proper alignment of images (registration) is carried out
by data post-processing using anatomical landmarks of fiducial markers based on either rigid
body transformation ignoring any deformation or more advanced non-rigid registration algorithms
compensating for movement/deformation of the subject. Such an approach benefits from the full
performance of the individual imaging modalities. Its obvious disadvantage is that it precludes
the simultaneous study of biological processes and that sample motion during the transfer cannot
be excluded. (2) By integrating more than one type of imaging technology into one functional unit
these issues are inherently addressed. Such a system would allow for simultaneous data acquisition
under identical physiological conditions and also simplifies the registration problem due to the fixed
geometries connecting both modalities. The technical challenge for an integrated solution is to
maintain the performance level of the individual techniques in the combined system, i.e., avoiding
or at least minimizing any potential interference between the systems. For biomedical research
such devices would be highly attractive as they would allow for multiplexed time-correlated
measurements of biological system in the same physiological or diseased state.
A prerequisite for combining two (or more) functional/molecular imaging approaches is the
availability of multimodal probes targeting the same biological process but using different reporter
moieties that can then be visualized by different modalities.
Pharmaceutics 2011, 3 244
This section describes the research efforts under way to combine optical imaging techniques
with other imaging modalities. It outlines the benefits of the different combinations to investigate
novel therapeutic or diagnostic approaches in animal models of human disease. A list with different
hardware based approaches to combine optical imaging techniques with other state-of-the-art
methods is given and applications concerning the specific combination are mentioned. To complete,
a short insight in multimodal probe design and its applications is included.
3.3.1. Multiplexing Information Using a Sample Support Compatible with Multiple Imaging
Modalities
A straightforward approach for multiplexing imaging information is the development of an
animal support, which is compatible with the different commercially available imaging modalities.
This support ensures a reproducible animal position and included fiducial markers visible by
both systems allowing a precise co-registration after the measurements. It is obvious that any
combination of imaging modalities is amenable to this approach provided the appropriate fiducial
markers are used. The crucial part in such experiments is the subject transport from one to the
other modality. Care has to be taken to avoid/minimize animal movements during the transport
and to maintain stable physiology e.g., by avoiding changes in body temperature. Alignment of
multimodal data is then achieved by post-processing as already described.
The potential of this approach was early demonstrated by combining DOT and functional MRI
(fMRI), both methods assessing changes in blood oxygenation, demonstrated similar temporal
responses in the somatosensory cortex evoked by electrical forepaw stimulation [74].
The first study combining FMT with MRI was carried out by Ntziachristos et al. [1] who
analyzed cathepsin B activation in 9L gliosarcoma in nude mice. By superposition of the
reconstructed fluorescence intensity distribution indicating protease activity and the gadolinium
enhanced MR image the correct localization of the optical signal in the corresponding MR brain
slice could be revealed. A related study of a mouse brain glioma model was recently performed
by McCann et al. [75] where FMT was applied to image protease activity in the tumor using
a commercial FMT system while the subsequently recorded MRI data provided the anatomical
reference. The authors claim that only the combined analysis of FMT and MRI data correctly
predicted the effects of chemotherapeutic intervention (Figure 5c) by calculating the ratio of
ProSense fluorescence (extracted from FMT) to tumor volume (extracted from MRI), yielding a
normalized protease activity which is here called protease activity concentration (PAC). Another
example was the protease activatable fluorescence probes designed to image atherosclerosis in
mice [76]. Due to the small size of atherosclerotic plaques and the variability in their distribution
across the vascular system, accurate localization of sites of protease activity with FMT is
challenging. To overcome this limitation a multimodal imaging cartridge that holds the mouse
and is compatible with both FMT and CT has been used. The mouse is slightly compressed
by two optically translucent windows in the cartridge preventing animal motion during transfer
between the modalities. In this work it was shown that FMT enables visualization of protease
activity at plaque sites as well as the effect of therapeutic interventions reducing plaque associated
inflammatory processes in a longitudinal manner. Registration of imaging data in the course of
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the study has been warranted on the basis of a high resolution contrast-enhanced CT angiography,
which provided anatomical landmarks [76] (Figure 4b).
By having a MR sample platform which is compatible with a bioluminescence system, it has
been shown that the accurate knowledge of tissue layers segmented from an MR image can improve
the bioluminescence imaging [77].
Finally, sequential nuclear-optical imaging using a planar imaging configuration has been
demonstrated in tumor bearing mice [78,79]. Selective accumulation of perfusion markers using
99m-technetium (99
m
Tc) marker as radionuclide emitting gamma photons and hematoporphyrin
as a fluorophore, has been demonstrated.
Even tri-modality systems combining CT/PET/FMT were proposed where the animal was
positioned on a mobile platform which is shifted on a rail from the PET/CT scanner to an FMT
scanner [80]. Other multimodality readouts can be achieved by placing the different systems
in close proximity allowing a fast shifting of the animal from one to the other modality. Such
a readout to improve the quantification of tumor burden in mice was performed by placing a
PET/CT scanner close to a bioluminescence system [81].
3.3.2. Hybrid Systems Combining Structural and Optical Imaging: Annotation of Anatomy with
Molecular Information
Even though significant progress in terms of spatial resolution and sensitivity has been
recently achieved in the field of FMT, the method is still far from accurately visualizing
biological information at spatial resolution comparable to structural imaging modalities such
as CT. This lack of accuracy is due to the severe scattering of light in a turbid medium
such as tissue, which leads to a loss of spatial information which deteriorates as the distance
covered by the light path exceeds the scattering path length (typically 1mm in tissues). Even
though the principles of light propagation are well understood, the exact solution of the
mathematical models that accurately describe the light distribution inside the imaged volume
remains extremely computer intensive. This is among other reasons due to the fact that simple
models with direct analytical solutions have difficulties in accounting for tissue heterogeneity
(including multiple tissue interfaces of arbitrary geometry), that the optical parameters for
the various tissues are known with a large degree of approximation and, more importantly,
greatly vary with the physiological state of the tissue (more specifically, it’s the oxygenation
state of the tissue which causes changes in the absorption properties of tissues-this very fact
is the basis of DOT), and that the problem is commonly underdetermined, i.e., the number
of independent data samples (i.e., the measurements corresponding to a source detector pair)
is insufficient for achieving high spatial resolution. Therefore the FMT reconstruction, which
is based on maps representing the two-dimensional light distribution on the surface of the
subject, can only be performed by introducing approximations, which in general represents
over-simplifications. Another reason is that a hybrid system providing structural information on
the anatomy (internal geometry), would help to implement more sophisticated models accounting
for the tissue interfaces and for the absorption and scattering properties within each type of tissue.
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X-ray CT/Optical imaging: X-rays are electromagnetic waves of short wavelength, which interact
with the constituents (mainly electrons) of the matter penetrated. Contrast in X-ray imaging
is based on the differences in attenuation coefficient of the various tissues. Conventional X-ray
images are two-dimensional projections of three dimensional objects; they are widely known as
a medical diagnostic tool. They exhibit weak contrast among soft tissues but high contrast
between soft tissue and bone and are therefore useful for detecting pathologies of the skeletal
system. By using contrast agents, which are electrodense materials, the contrast among soft tissues
may be enhanced. The objective of CT is to obtain three-dimensional anatomical information
by reconstruction of the distribution of attenuation coefficients. This is achieved by recording
multiple projections of the object from various angles and applying reconstruction procedure via
back-projection [28]. For representation the three-dimensional data stack is re-sliced to yield
two-dimensional cross-sectional images.
A first successful attempt to combine CT with FMT based on sequentially recorded data was
reported in 2005 [83]. In this study a parallel plate FMT imager [64] was used to image a
cancer model with GFP expressing glioma cells implanted into the lungs of nude mice. For FMT
experiments the animals were positioned vertically in a chamber consisting of parallel glass plates,
which was filled with refractive index matching fluid. The reconstructed FMT data set was then
manually aligned to the corresponding CT data to obtain adequate data co-registration. A major
disadvantage of this FMT setup is the animal placement in a liquid filled imaging chamber, which
renders studies in the head region of an animal very difficult. Therefore, multimodal sequential
imaging setups using a liquid free 360◦ FMT setup, in which the specimen is placed vertically
on a rotating stage have been developed [71,84]. The anatomical reference was in both studies
acquired afterwards with a µ-CT system. Such a setup was used to visualize the deposition of
amyloid-β plaques in a murine model of Alzheimer’s disease. Data registration was achieved
by an affine transformation mapping the animal’s surface as obtained using a surface projection
technique in the FMT setup [72] with the surface derived from the CT data set. Once registered
the CT slices could then be used as anatomical reference for the corresponding optical slice. The
plaque load in a transgenic APP23 mouse strain could be visualized following the administration
of the NIR dye AOI987 [85], an oxazine dye known to bind selectively to the amyloid plaques in the
mouse brain. This hybrid imaging approach allowed monitoring the increase in plaque load during
disease progression [86]. Still the vertical posture of the animal for the FMT measurement system
is not satisfying due to gravity induced displacement of organs/tissue compared to the horizontal
placement in common CT scanners. Therefore it is desirable to mount the optical components on
a CT gantry, which rotates around the animal in horizontal posture [87].
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Figure 4. Applications: (a), Schematic of a hybrid FMT/CT system. Perpendicular
to the X-ray tube and flat panel detector axis the FMT instrumentation is mounted
consisting of a laser source, a scanning device and a CCD camera. All components are
mounted on a rotating gantry holding the sample in its center.(b), Sequential FMT/CT
example of artherosclerotic plaques in mice. A through C, Image co-registration is
based on fiducial landmarks (arrows) that are incorporated into the animal holder
and are identifiable on CT (A) and FMT (B). The software co-aligns these fiducial
markers to created a hybrid data set (C). Fluorescence signal in the aortic root of
an apoE−/− mouse is encircled. D and E, 2-dimensional FMT/CT long axis views
of apoE−/− mice injected with respective protease sensors. Fluorescence signal is
observed in the aortic root and arch, regions with high plaque load. G and H, CT only
views of D and E. Arrow heads depict vascular calcification, likely colocalizing with
plaques. J through O, 3-dimensional maximum intensity projection of hybrid data
sets show skeletal and vascular anatomy and the distribution of fluorescence signal.
Most signal is observed in the root and arch. S and T, FMT/CT after injection of
respective sensor into wild-type mice (Adapted from [76]; reprinted with permission).
(c), Hybrid imaging example of a lung inflammation mouse model. (a) Cryoslice images
overlaid with normalized fluorescence image; reconstruction using weighted segments
regularization (b) transversal slices and (c) coronal slice (Adapted from [82]; reprinted
with permission).
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A successful implementation of a combined FMT/CT setup with this gantry approach was
described by Barber et al. [88], who fixed the optical components and the CT components on
two rotating gantries side by side on parallel planes. The sample platform is centered in the
symmetry axis of the gantries which allowed a translation from the optical to the CT part without
removing the platform. A study using cylindrical and arbitrary shaped phantoms with different
inclusions containing the fluorescent dye ICG demonstrated the potential of the system for in
vivo applications. By including information on scattering and absorption parameters derived
from intrinsic optical measurements (with DOT) using this setup, the authors could improve the
reconstruction quality for the embedded fluorescent object [89]. The suitability of the system for in
vivo application was recently shown in mouse experiments: Both the location of a superficial and
a deep seated fluorescent inclusion could be accurately reconstructed [90]. Further improvements
in reconstruction accuracy have been achieved by incorporation of structural information derived
from the CT and of the functional background information from DOT.
Another rotating gantry approach with the optical components for the FMT imaging mounted
on the CT gantry with the optical axis at a right angle to the axis comprising the X-ray
source and detector has been described by Schulz et al. [91](Figure 4a). This alignment allows
the simultaneous acquisition of both data sets, which are inherently co-registered. Structural
information from CT was used to guide the reconstruction of FMT data. The method was used to
study focal lesions in the brain [91] and the lungs [82] of mice (Figure 4c). A mixture of 1µMol/L
Alexa750 fluorochrome was implanted stereotactically into the right brain lobe at a depth of 4mm
in euthanized mice. The location of the sample could be adequately reconstructed with both
modalities. In a further validation study protease activity was assessed in a lung tumor model.
A protease sensitive fluorescence probe was tail vein injected 24h prior to imaging. Distinct
fluorescence signal has been observed in the lung of the mouse following cleavage of the probe by
tumor secreted proteases [92]. Feasibility of accurate localization of lesion in the brain and in lung
tumors with help of prior structural information was demonstrated and illustrated the potential
future of this application.
The design of combining the free-space FMT with CT on a vertically mounted gantry rotating
around a sample is attractive as animals can be scanned in their natural horizontal posture. Yet,
the irregular shape of the object renders reconstruction of FMT data challenging. An alternative
approach involves an arrangement of FMT and CT sources and detectors in a horizontal plane
with the sample rotating around a vertical axis. This would allow immersion into refractive index
matching fluid to achieve regular geometry for data reconstruction [93,94]. Feasibility of this design
was successfully demonstrated in experiments using standardized tissue phantoms and euthanized
animals carrying a esophageal tube filled with a fluorescence dye. Da Silva et al. [95] used a similar
system for studying lung metastasis in nude mice. In vivo measurement were carried out following
administration of a transferrin/Alexa 750 conjugate and demonstrated the presence of fluorophore
in the lung, liver and bladder overlaid on a structural image showing the animals skeleton for
accurate anatomical localization of the fluorophore distribution. A similar setup was built to
combine bioluminescent tomography and CT imaging [96]. The authors demonstrated an increased
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localization and quantification accuracy in bioluminescence tomography for a heterogeneous mouse
model incorporating the segmented CT data compared to a standard homogeneous mouse model.
Due to the limited tissue penetration of light, FMT/CT systems are largely confined to
preclinical applications, although optical imaging is used for very specific applications in
clinics such as breast- and testicular-cancer imaging, arthritis and neonatal brain investigations.
Nevertheless, clinical systems have been designed as well. Today, X-ray radiography is the most
widely used screening methods in clinics, e.g., in screening for mammary carcinoma or articular
cartilage damage in osteoarthritis. Although X-ray provides high resolution in differentiating
bones from soft tissue the image contrast between different soft tissues is very low. Therefore,
adding functional or molecular information would definitely enhance the diagnostic accuracy.
A characteristic of invasive tumor is sustained angiogenesis, which is associated with high
microvascular density and potentially also a high tumor blood volume. Hence combining structural
imaging with a method that provides hemodynamic information such as DOT, which measures
local values of scattering and attenuation coefficients, which are largely governed by the absorbers
contained in blood (hemoglobin and oxy-hemoglobin), might be diagnostically relevant.
Therefore, a DOT imaging system compatible with a mammography device has been
developed [97,98] for clinical trials. In these studies, the measurements where sequentially recorded
without moving the breast. DOT measurements revealed in increased absorption in the tumor
region indicative of increased blood volume and alterations in oxygen saturation. The tumor
location was verified by X-ray imaging.
The possibility to access the molecular and cellular signature of osteoarthritis by diagnosing
cartilage abnormalities and alterations in composition of synovial fluid in joints via absorption and
scattering spectra measurements with DOT was shown by Yuan et al. [99]. The optical properties
in the fluid which is changing depending on the inflammation state is measured with DOT. The low
spatial resolution caused by multiple scattering of light was improved by incorporating structural
a priori information for the optical reconstruction. DOT data quality was such that joint-space
abnormality in osteoarthritic joints could clearly be identified [100], highlighting the potential of
the multimodal concept for clinical diagnosis and treatment control.
Recently XLCT was proposed as a new combination of structural and molecular readout within
the same system [101,102]. It is based on the selective excitation and optical detection of X-ray
excitable phosphor nanoparticles. These nanoparticles can be designed using various methods
[36,37] to emit NIR light when excited with X-rays and are therefore well suited for biomedical in
vivo application. Imaging can be performed simultaneously and no further optical light source is
needed for excitation, the particles are excited to emit light by high energy photons produced by
interaction of X- and γ-rays with matter through photoelectric absorption or Compton scatter.
The major advantage is the benefit of having no autofluorescence produced by an optical excitation
source and that also very few photons detected by the camera are used for a precise fluorophore
localization. As this imaging technique is very new, there are currently only proof of principle
experiments in phantoms available and a real in vivo imaging proof is still missing.
MRI/Optical imaging: MR images represent a weighted distribution of hydrogen nuclei (protons)
in the body, the principal signal contributors being the protons of water and adipose tissue.
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Nuclei with odd proton and/or neutron number such as the proton possess a magnetic moment,
i.e., behave as tiny magnets. In a strong magnetic field magnetic moments align either parallel
or opposed (anti-parallel) to the field direction, with slight excess in the parallel orientation
leading to a net macroscopic magnetization. Irradiation with electromagnetic waves of a certain
frequency (the Larmor frequency, which corresponds to the difference in energy between the
parallel and anti-parallel state) will excite the spin system and generate observable non-equilibrium
magnetization that is measured using an MRI receiver coil. The MRI signals decay by relaxation
processes (T1,T2,T2*) that are tissue specific and constitute the source of the high soft-tissue
contrast of the method. The high magnetic field strengths (>1.5T) and the restricted access to
the sample render a hybrid design involving the incorporation of the FMT into an MRI scanner,
rather challenging. Non-magnetic optical components have been developed for this purpose.
Instrumentation and theoretical development for combining MRI with optical imaging was
driven by the need of an efficient detection for early stage breast tumor in women. Breast tissue
is relatively weakly absorbing and therefore lend itself for optical imaging studies. As discussed
in the previous section the structural and dynamic contrast enhanced MRI imaging method was
complemented by optical imaging targeting tumor angiogenesis. The sensitivity of the optical
readout for assessing the tumor vasculature was increased by using the fluorescent dye ICG,
an intravascular agent approved for clinical use [5]. An overview about technologies for breast
cancer management with optical and combined optical and MR systems is given in [104]. FMT
may become a powerful tool in breast imaging once target-specific fluorescent agents capable
of highlighting physiological processes associated with cancer pathology become available for
diagnostic applications. It is not surprising that breast studies are in the focus of FMT/DOT
method development. Experiments using “breast-like” phantoms with fluorescent inclusions [105]
or simulations based on MR images of breast tissue [106] should demonstrate the potential of
these combined techniques.
Nevertheless, the focus of studies addressing hybrid FMT/MRI systems currently relate to
preclinical applications. All solutions found in literature uses a fiber based FMT as an insert into
either a clinical MRI magnet or a preclinical MR scanner (see Figure 5a). For this setup the fibers
have to be brought in physical contact with the sample. Such design constitutes a compromise
in terms of imaging performance for both modalities. Measuring animals using a human scanner
with a large bore compared to the animal will compromise spatial resolution and thus the quality
of structural information. On the other hand performance is affected by light loss due to inevitable
loss in coupling to the fibers guiding the light to the detectors located outside the MRI magnet
and that these fibers recover light only from a small part of the surface. Moreover such systems are
bulky and restricted with regard to the number of source detector pairs and also the flexibility in
potential excitation schemes. Nevertheless such a system was successfully implemented and proof
of concept was demonstrated for mouse brain where human glioma tumor cells were implanted
intracranially [107,108]. The tumor area was segmented according to the MRI image and an
improvement in tumor localization could be shown by applying the prior knowledge. Recently the
setup has been used to assess the EGFR status in an animal model of brain tumor. Tissue regions
segmented on the basis of the MR image were used to guide the reconstruction of fluorescence
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distribution of the NIR fluorescent dye conjugated to the EGF ligand [109]. The setup comprises
a single ring of fibers connected to light sources and detectors and therefore allows the fluorescence
reconstruction of one single slice. The corresponding slice in the MRI data is identified on the
basis of fiducial markers mounted at the fiber tip in contact with the animal. Similar systems has
been developed for DOT imaging to measure changes to study rat cerebral oxygen consumption
[110] or to visualize increased blood volume in rodent breast tumor models [111]. In all cases,
structural information was used for the reconstruction of optical data.
Integrated DOT/MRI systems have also been described for clinical applications [5]. For
example, hybrid imaging has been used to compare the fMRI signal evoked by an external stimulus
with hemodynamic changes assessed by DOT. Consistency in spatial localizations of fMRI and
DOT signals in activated brain regions was demonstrated. Structural MRI information has been
used to generate a patient specific head model [112] or to fuse fMRI and DOT information into
one model to generate a joint estimate of the underlying physiological contrast [113].
Ultrasound/Optical imaging: In this section we will not discuss opto-acoustic imaging, in which
ultrasonic waves elicited by light absorption are detected. This is a very exciting new modality
with great potential both in pre-clinical and clinical studies, but it is out of the scope of this
review. For further information on this technique we refer to [114,115]. We will focus on the
use of ultrasound imaging providing pure structural information as anatomical reference for FMT
images or to improve FMT/DOT localization.
For example, ultrasound images have been used for verifying the correct spatial localization
of fluorophore distribution in a phantom mimicking prostate in a study using a newly developed
transrectal probe for the fluorescence measurements [116]. The two data sets have been recorded
sequentially. Clinical applications were once more driven by the need for improved detection of
malignant breast lesions. Structural information derived from ultrasound was used to segment
breast tissue into tumor and normal tissue to guide the optical reconstruction [117]. This study
was performed by a combined ultrasound/DOT imager [118] where the ultrasound array was
centrally placed in a plate comprising the source and detector fibers for DOT imaging. A
related study with a further developed instrument was performed by Zhu et al. [119]. A recent
clinical application deals with image-guided prostate tumor biopsy using an ultrasound/FMT
setup. Standard of care in supposed prostate cancer is an ultrasound guided biopsy. It has been
speculated that hybrid ultrasound/FMT might improve the accuracy of the biopsy procedure [120].
Phantom experiments with a trans-rectal ultrasound coupled NIR device could show the improved
fluorophore localization from the optical reconstruction with help of prior knowledge of ultrasound
structural information [121]. The same instrument was used to investigate transmissible venereal
tumors in vivo in a dog model. Tumor tissue displayed significantly different scattering and
absorption coefficients as compared to the normal prostate tissue. There was good agreement in
tumor localization between ultrasound images and the reconstructed optical images [122].
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Figure 5. Applications: (a), Schematic FMT insert for a clinical MRI system.
The system consists of source/detector fibers which are mounted circularly around
the sample and which were fixed in the MR coil. The detector and the sources are
located outside the magnetic field (b). Example of a simultaneously acquired data set
with a setup presented in (a). Representative images of fluorescence yield overlying
the corresponding MR images. Each column provides results for a single animal
from one of the three mouse populations (U251 tumors, 9 L tumors, and controls,
respectively). The rows show images recovered using the hard-prior technique (I),
the soft-prior technique (II), and an unguided reconstruction technique (III) (Adapted
from [103]; reprinted with permission). (c) Example of a sequentially acquired data set
showing that chemotherapy increases the ratio of protease activity to tumor volume.
(a), (c) Combined FMT/MR imaging of a mouse bearing an implanted glioma at day
0 and day 6. (b), (d) Combined FMT/MR imaging of a chemotherapy treated mouse
bearing a similarly sized glioma at day 0 and 6. (e) Quantification of the effects of
chemotherapy on protease activity and tumor size. Protease activity concentration
(PAC) was significantly altered by the end of a 5 day course of chemotherapy. This
difference became even more pronounced at the end of the experiment (day 15 after
chemotherapy). (Adapted from [75]; reprinted with permission).
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3.3.3. Hybrid Systems Combining two Functional/Molecular Imaging Modalities
Combining optical with a second functional imaging modality such as PET, SPECT
or functional/physiological MRI (e.g., dynamic contrast enhanced MRI to assess vascular
permeability) allows investigating two concurrent biological processes using two distinct
target-specific imaging probes or generating multiplexed readouts of the same process using
fused probes that contain two reporter moieties. A variety of research applications is given
in [123] e.g., cross validation of both methods and the use of both modalities in intraoperative
procedures. The hardware development in this field is driven by integrating the two methods
into one system allowing the simultaneous data acquisition of a sample, which is critical when
correlating functional readouts.
SPECT/PET/Optical imaging: An optical/PET detector concept was proposed in 2004 which
is capable of efficiently detecting the 511 keV photons emitted from PET radiotracers and to
simultaneously measure faint bioluminescence signals from luciferase reporter genes utilizing
transparent scintillators [124,125]. The concept [126,127] was successfully tested on the bench
with phantom measurements for high energy 511keV and visible low energy 2–3 eV photons [128].
However, in vivo proof of principle of this approach is still lacking. Simulations for the light
propagation indicated that accurate localization of bioluminescence sources within the simulated
phantom mouse should be feasible [129]. Yet, accurate localization required knowledge of the
optical properties of the tissues in vivo [130] and by spectrally resolved bioluminescence signals,
which both appear difficult under in vivo conditions. Another set of simulations was carried out to
evaluate the PET characteristics of the detector [131]. Apparently, modeling predicts feasibility
of the approach yet an in vivo application using this combined imaging detector has not been
reported. A potential issue with the device might be the so-called afterglow effect, i.e., low energy
photons generated by the reaction of high energy photons with the scintillation crystals [132].
These produced low energy photons have similar properties as the photons emanating from
the bioluminescence probe and can therefore not be discriminated, which might lead to a
misinterpretation of the optical measurements. Depending on the scintillation material used these
effects can be reduced to an amount that simultaneous signal read out should be possible.
A more sophisticated hardware development was shown by Peter et al. [133] allowing not
only bioluminescence but also fluorescence measurements using the same setup. It consists of two
different detector rings, an outer PET detector ring and an inner ring comprising optical detectors.
The laser light is coupled into the system through the gaps between the detector elements of both
rings. First phantom experiments showed that the system is sensitive for detecting micromolar
fluorescence dye concentrations and nuclear activity at a microcurie level. Again, in vivo validation
has not yet been reported.
An attractive role of combined PET/FMT is to validate FMT as a surrogate for the nuclear
imaging modality, in particular for preclinical application. The use of FMT would offer several
advantages: (1) FMT is significantly cheaper then PET, (2) fluorescent tracer are stable in contrast
to positron emitters that are characterized by short half lives and (3) the fluorescent signal can
be modulated as seen, e.g., for activatable probes. The major disadvantage of FMT as compared
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to PET is quantification. Therefore it was important to analyze whether and how well probe
concentrations and spatial signal distributions of hybrid PET and optical tracers were correlated:
Both phantoms and in vivo studies in mice bearing subcutaneous tumor xenografts have been
carried out [134]. As an anatomical reference the CT image was used captured with a hybrid
PET/CT system. The authors reported high values for the correlation and concluded that FMT
in fact could be used as a sensitive and quantitative tool assisting in the development of PET
reporters. This question was further addressed by Garofalakis et al. who studied deep seated
organs like the kidney [135]. A mixture of a fluorophore and a 18F labeled oligonucleotide, that
has been shown earlier to accumulate in the kidney, was intravenously injected into the mouse
prior the PET and FMT measurements. By analyzing the reconstructed PET and the FMT scans
with help of an anatomical CT image they found a discrepancy of the geometrical volumes but
nevertheless a good correspondence of tracer concentration as determined by the two modalities.
This led to the conclusion that free-space FMT is capable of providing information comparable
to PET even for deep seated organs, although FMT has some sensitivity limitations compared
to PET.
A peculiarity of combining PET imaging with optical imaging is Cherenkov radiation, which
can be observed as a side-product of positron emitting radiotracers. The high energy positron
emitted by the radioisotope may transiently exceed the speed of light in tissue and therefore
satisfies the requirements for generating Cherenkov radiation, i.e., the charged particle induces
local polarization along its paths through the medium and radiation is emitted when the excess
energy is released and system returns to equilibrium. The Cherenkov radiation has a continuous
spectrum from the near ultraviolet to NIR and is emitted at a particular angle (which depends on
the particle velocity and the velocity of light in medium). The intensity is inversely proportional
to the square of the wavelengths. Cherenkov light was successfully detected in tissue phantoms
using optical planar imaging in combination with PET using wells of the radionuclides 18F and
13N and in vivo in a tumor xenograft model using [18F]-FDG injection [136]. These results where
confirmed by another study using 18F radionuclides and further validated using 131I and 90Y, two
widely used isotopes for radiotherapy [137]. The usage of Cherenkov light is very limited to the
study of subsurface structures as the emission wavelength and the intensity is much higher in the
UV than in the red spectral domain.
3.4. Use of Prior Information for DOT/FMT Reconstruction
The achievable image quality and resolution, particularly the spatial resolution is
limited by the ill-posed, underdetermined and ill-conditioned nature of imaging with diffuse
light [8,30]. Improvements in resolution and imaging performance can be achieved by incorporating
anatomical (CT, MRI) or functional (PET) information, so-called image priors in the DOT/FMT
reconstruction process.
Tissue classification is achieved by segmentation of anatomical images. This knowledge is
then introduced in the reconstruction process by adapting the regularization procedure through
the inclusion of a so-called penalty function. The impact of these procedures was recently
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demonstrated on small animal FMT/CT data sets and simulations in a lung inflammation
model [82].
Apart from structural there are functional priors. The diffusion equation contains terms of
absorption and scattering which need to be defined to perform the forward modeling. This is
referred to functional prior information and can be incorporated in the reconstruction by assigning
appropriate optical parameters to anatomical regions in the forward problem. In a paper by
Hyde et al. [138] the effect of optical properties on the reconstruction quality using priors was
examined for a normalized Born approximation. The authors conclude that the prior information
in the inverse problem alone can improve the performance and a further enhancement could
be achieved by an improved diffusion modeling with average optical properties assigned to the
segmented tissue. The value of using functional a priori information was demonstrated by
DOT guided fluorescence tomography [139] for which an improved distribution of the accurate
fluorophore concentration has been computed in phantom study when reconstructing data
obtained with a 360◦ non-contact DOT/FMT system. Others also emphasize the significance
of functional a priori information [140,141] in terms of localization accuracy. The role of having
both functional and structural a priori information was studied in multi-compartment phantoms
producing a heterogeneous background [142,143]. The heterogeneity in the attenuation coefficients
was accounted for when analyzing DOT images acquired prior to the FMT data.
3.5. Multimodality Probes
Multimodality probes can simplify simultaneous imaging with hybrid systems due to single
probe administration revealing a contrast enhancement on both modalities. A detailed description
of the synthesis and production procedure is beyond the scope of this review article. The interested
reader is referred to the references in the following mentioned citations. Designing a probe for
multimodality imaging is most prominent a combination of optical and radionuclide labeled probe
both imaging functionality of a biological process. A tumor study of a human melanoma xenograft
model combining a 111In chelator diethylene-triamine-pentaacetic acid and a NIR fluorescent dye
showed an improved resolution and sensitivity with optical planar imaging for superficial lesions
compared to sequentially acquired γ-scintigraphy images providing sensitive detection of deeper
structures [144]. A similar study combined bioluminescence, fluorescence, γ-scintigraphy and
SPECT readouts [145]. A complementary imaging strategy for optical and scintigraphic imaging
involves the incorporation of and activatable fluorescent molecular system into a radio-labeled
cleavable peptide with identical pharmacokinetics but different reporting strategies [146].
An attractive concept is the development of combined probes resulting in contrast enhancements
on both modalities. Josephson et al. [147] developed an MRI contrast agent based on magnetic
nanoparticles with an enzymatic activated NIR fluorophore. This probe can be localized with
MRI while providing information on molecular processes (protease activity) by fluorescence
imaging techniques. Another dual fluorescent/MRI probe based on liposomes was developed by
Shan et al. [148] which enhanced on one hand the tumor morphology in the MR images and
allowed at the same time the quantification of the biomarker expressed in the tumor using NIR
fluorescence optical imaging. Recently the in vivo application of an up-converting luminescence
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probe for optical imaging in combination with a paramagnetic MRI probe enhancing the MR
contrast was reported as a future concept to detect and image biological targets in a dualmodality
manner [34].
As an alternative exogenously administered probes, multimodal approaches may be also based
on reporter gene assays, in particular fusion proteins combining bioluminescence with thymidine
kinase as PET probe [149]. Such dual optical-nuclear imaging approaches might yield improved
quantification accuracy [150,151].
For example, fusion reporter gene assay have been used for non-invasive molecular imaging of
protein-protein interactions in vivo with help of PET and ex vivo fluorescence microscopy [152].
Even a triple-fusion reporter gene has been proposed as an efficient tool for multimodality imaging
combining fluorescence, bioluminescence and nuclear imaging techniques to investigate molecular
processes [153–155].
4. Application in Pharmaceutical Research
The potential contribution of non-invasive imaging to the drug discovery and development
process is illustrated in Figure 6. The process starts with the identification of a potential drug
target, i.e., molecular entity or process that is associated with the pathological condition and
should be modified by the therapeutic intervention. Molecular drug targets include membrane
receptors and channels, enzymes, proteins in signaling pathways, nuclear receptors, genes and
the gene expression machinery. Target identification is based on clinical findings, e.g., altered
expression in pathologic tissue, gene linkage studies, mechanistic consideration, etc. Validation
of a target is of prime importance in a drug discovery program—a potential role for molecular
imaging. There are numerous imaging studies illustrating the expression of molecular targets
under pathological conditions. The next step in the cascade is the development of a screening
assay suited for screening large compound libraries. After validation, compounds of interest will
be further evaluated in animal models of human disease. Finally, the most important compounds
will enter the clinical phase for early exploratory studies and eventually full clinical development.
4.1. Target Validation: Expression of Disease-Specific Molecular Targets
The conventional method to assess the presence of a molecular entity in vivo is the use of a
target specific probe consisting of a targeting moiety linked to a reporter moiety. The targeting
moiety typically consists of a low molecular weight drug analog, small peptide, antibody or
antibody fragment, characterized by high affinity to their molecular target. The reporter moiety
depends on the imaging modality used, for optical imaging it is typically a fluorescent dye or
a quantum dot. It is important that the linking of the two molecular scaffolds does not affect
the pharmacophor of the targeting molecule. This approach has been widely used to visualize the
expression of receptors/antigens in tissue. Examples are the visualization of somatostatin receptors
in neuroendocrine tumors in the mouse using a stabilized somatostatin analogue (octreotide)
labeled with the fluorescent dye Cy5 [156], or of the expression of a fibronectin domain in activated
endothelium that is associated with tumor neo-angiogenesis using a single chain antibody fragment
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labeled Cy7 [157]. Both molecular targets qualify as potential drug targets. Octrotide and related
compounds are clinically used as anti-tumor agents, and inhibition of specific receptors expressed
on activated endothelium may inhibit neo-angiogenesis. A disadvantage of this imaging strategy
is that both target-bound and unbound probes will contribute to the signal. Correspondingly,
contrast, or to more precise, the TBR is governed by the expression level of the molecular target
and the pharmacokinetic properties of the probe molecule itself. If unbound probes clear slowly
from the system, it may become difficult to achieve high TBR values. This has prompted the
concept of activatable probes.
Figure 6. Multimodality imaging in drug discovery: Molecular imaging contributions
are indicated in light red and relate to aspects addressing expression, PK and drug
effects at a molecular level (receptor interaction and signaling). Physiological and
structural readouts of drug efficacy are indicated in dark red.
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The fluorescence signal depends on the molecular environment of the fluorophore, which may
affect the fluorescence wavelength of the fluorescence quantum yield. This has been exploited
in the development of molecular beacons or self-quenched probes such as protease activatable
probe [39]. In this probe design fluorescence is quenched unless a specific peptide motif is
cleaved by the respective protease. For such probes, unprocessed circulating probe molecules
will not contribute to the signal, which leads to a significant increase in the TBR. This
probe concept has been used to study protease expression in tumors, which are among others
associated with the degradation of the extracellular matrix and hence to the invasive nature of
the tumor. Proof-of-concept was established in subcutaneously implanted human fibroscarcoma
xenografts [39], and related probes have been used to study orthotopic gliomas in mice [1],
mammary murine tumors in lung metastases in mice [69], or human mammary adenocarcinoma
cells implanted in the mammary fat pad [44] to mention a few studies. Aside from their association
to tumors, protease are expressed in inflammatory diseases such as atherosclerosis or rheumatoid
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and osteoarthritis. Optical imaging and FMT have been applied to monitor protease activity in
genetically engineered mice that expressed a high burden of atherosclerotic lesions [76] and in
collagen-induced models of rheumatoid arthritis [47].
4.2. Characterization of Disease Models/Disease Processes
Multimodal imaging has been widely used to characterize animal models of human disease based
on structural, functional/physiological, metabolic, cellular and molecular readouts [158]. Concepts
for targeting disease-specific molecular entities has been discussed in the previous section. Yet,
the reader should be aware that not every specific molecular target presented by pathologically
transformed tissue qualifies as drug target. For example, the occurrence of aggregated β-amyloid
molecules in the brain parenchyma is a histopathological hallmark of Alzheimer’s disease and
therefore potential target for Alzheimer’s diagnostic. Not surprisingly a large number of molecular
imaging probes has been developed including some fluorescent molecules such as AOI987, an
oxazine dye. Planar fluorescent imaging as well as FMT have been applied to monitor the
deposition of β-amyloid plaques in murine models of Alzheimer’s disease [85,86]. While not a
therapeutic target per se, the method can be readily applied to stage the severity of the disease
and to assess the efficacy of plaque modulating therapy. It is in principle translatable into the
clinics, the clinical version of the assay is based on PET technology [159].
Visualization of the presence of a specific cell population and in particular their migration is
of relevance for many applications in biomedical research. Inflammatory processes involve the
orchestrated infiltration of various cell types such as lymphocytes, leukocytes and monocytes.
Stable cell marking using bioluminescent and fluorescent reporter proteins is a commonly used
approach to follow the migratory properties of immune competent cells. For example, a transgenic
mouse model with a GFP reporter assay was established [160] and was further modified later on
to study the response of the immune system after brain ischemia by imaging T lymphocytes [68].
Alternatively monocytes might be efficient labeled in situ using nanoparticulate moieties such as
quantum dots. This approach has been applied to monitor the migration of monocytes to the
sentinel lymphnodes [161]. Similar cell marking strategies have been applied to stably marking of
tumor cells for monitoring the formation of brain liver and bone metastasis [49].
The function and processes involved in the immune response in different disease models can
be investigated and quantified with FMT techniques. An interesting approach was chosen by
Zaheer and coworkers [48] who constructed a NIR fluorescent bisphosphonate derivative that
binds to hydroxyapatite which is used during bone formation and is produced by osteoblasts.
Therefore they were able to study osteoblastic activity in skeletal developments in mice. Recently
a fluorescence reporter probe was designed whose activation by cathepsin K was shown in osteoclast
cells [162]. These examples showed the potential application for optical molecular imaging in fields
where the research activity is strongly focussed on high resolution technologies such as CT or MRI.
It was even possible to quantify the readout with help of FMT which was a novelty in the field.
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4.3. Biomarkers to Assess Drug Efficacy
Biomarkers are objectively measurable quantities of prognostic quality that can predict how
a pathology evolves or if there will be an effect due to a therapeutic intervention. For example,
using AOI987 it has been shown that the plaque load in transgenic models of Alzheimer’s disease
increases as function of age of the mice [85], correspondingly the plaque load may be considered
as a marker of disease severity. Similarly, one would expect a reduced plaque load in the case of
a plaque modulating intervention. On the other hand a biomarker is not necessarily a surrogated
endpoint. If we stay with our example, it is not warranted that a reduced plaque load will
translate into an improved behavioral outcome, and if we translate into clinical situation, into
improved cognitive performance. It is important to realize the difference between biomarkers and
surrogates: Surrogates are validated measures that substitute for an endpoint (e.g., survival of a
cancer patient), while a biomarker gives information whether the patient will respond to treatment.
To what extend this predicts longterm outcome remains to be shown. Such biomarkers are highly
attractive when studying chronic diseases.
Alternatively biomarkers may yield information on the validity of the pharmacological
principle. As discussed in Section 4.1 high protease expression is associated with different
diseases and inhibition of protease activity is therefore an attractive therapeutic concept, e.g.,
in cancer or inflammatory diseases. The protease imaging methods discussed may be used to
evaluate such drugs. For example it has been shown that in the collagen-induced arthritis
model fluorescence imaging using protease activatable probes accurately captures the effects
of methotrexate treatment [47]. Similarly, administration of matrix metalloproteinase (MMP)
inhibitor prinomastat reduced the signal elicited by protease activatable probes in HT1080
fibrosarcoma xenografts [38]. In both cases, the imaging experiment revealed information that
the drugs reached their molecular targeted and inhibited the enzyme activity as expected. Wether
this translates into an improved outcome, i.e., inhibition of inflammatory processes and reduction
of joint destruction in the arthritis model, or tumor shrinkage and eventually animal survival in
the cancer study remains to be shown.
5. Potential and Limitation of Fluorescence Imaging
5.1. As Preclinical Research Tool
There is no doubt that the fast development of new reporter technologies had a significant
impact on the role of fluorescence imaging in preclinical research. Optical reporter systems are
in general stable and therefore suited for studying biological processes with time scales of days
or weeks. On the other hand, the actual measurement process in live animals is rather fast, in
particular when focusing on two-dimensional techniques, enabling the necessary high throughput
for compound evaluation.
Luminescent signals can be modulated by molecular processes. This is a highly attractive
property as probes can be designed in such a way that they generate a signal when the interaction
with the molecular target takes place. Examples discussed are protease activatable probes which
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only yield a signal, when the protease specific peptide motif is cleaved [39]. This will result in a
high TBR, as non-processed probe should not contribute to the fluorescence detected. Such probe
designs are not conceivable for nuclear imaging approaches.
Advanced optical imaging techniques such as FMT provide quantitative information on local
fluorophore concentration, which is critical e.g., when comparing the efficacy of different drugs.
Optical imaging is a non-invasive research tool and does not cause radiation damage, which might
be an issue with CT. With modern FMT systems imaging is no longer confined to superficial
structures. Also sources located at distances of 10 to 20 mm from the surface can be accurately
located and quantitatively assessed.
The principal technical limitation of FMT is the poor spatial resolution rendering the allocation
of a fluorescent signal to a specific anatomical structure difficult. This is due to the limited number
of source-detector pairs available for data reconstruction and the relatively crude models used for
photon propagation in tissue, which is based on simplifications that most likely are not always
appropriate. In addition, tissue optical parameters are not well defined. These issues have been
addressed in part by combining high resolution structural imaging modalities with the optical
readout either via sequential or simultaneous data acquisition. Considering actual anatomical
information in the data reconstruction better confines the problem.
While it is straightforward to tune the excitation and emission wavelengths of organic dyes to
fit the wavelength domain suitable for in vivo imaging, this is quite an issue when using fluorescent
protein as reporters. For example GFP is characterized by high brightness (high quantum yield),
but unfortunately in the wavelength range around 490 to 510 nm, in which absorption is an
order of magnitude higher than in the NIR region. In addition, tissue autofluorescence is high
at these wavelengths and will compromise TBR achievable. Autofluorescence of tissue caused by
the excitation wavelength is always an issue in fluorescence imaging but can be strongly reduced
by using further red shifted excitation wavelength [163]. Autofluorescence limits the capability
of fluorescence imaging approaches to resolve deep seated structures as the penetration depth of
green light is limited and the emitted light is strongly attenuated in tissue. Unspecific fluorescent
signals can also originate from the animal’s chow and can be eliminated by using a chlorophyll-free
diet [164].
There have been significant efforts finding new proteins or genetically modify existing ones
in order to shift the absorption and emission maxima to the red and NIR spectral domain with
considerable success [31]. Yet the wavelength shifts achieved are not yet sufficient and the quantum
yield of theses mutated proteins is significantly lower than that of GFP. Very recently a first report
on an infrared fluorescent protein has been published [165].
A further factor impairing fluorescence imaging is skin pigmentation when using standard
C57B/L6 mice. In areas of dark black pigmentation on the skin after fur removal, imaging may be
severely compromised or virtually impossible due to enhanced light absorption. The use of nude
mice could be a solution, but their use might be limited in many cases due to their compromised
immune suppression. Also, most transgenic mouse lines exist on C57B/L6 or 129 background and
are not available on a nude mouse background.
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Today fluorescence imaging allowing whole body scanning in mice is a widely used methodology
in experimental biomedical research. The method is sensitive, selective relatively cheap and
allows for reasonable throughput. By carefully addressing the limiting factors, the method can be
efficiently used to study molecular processes in vivo.
5.2. As Translational Research Tool
DOT imaging was first introduced as a clinical diagnostic tool for imaging the female breast.
Breast tissue has relatively low attenuation and scattering coefficients and is therefore suitable for
optical imaging. DOT was evaluated as screening modality for mammary carcinomas, which could
be clearly visualized due to abnormal hypervascularity and increased hemoglobin absorbance.
TBRs might be enhanced by administration of intravascular fluorescent dyes such as ICG [166].
Fluorescence enhanced imaging showed potential to replace the harmful and uncomfortable
mammography as the gold standard. Recently an optical device to investigate prostate cancer was
developed, which appeared promising to replace in the near future the painful clinical standard
approach of biopsy [121], and DOT has been suggested as screening device for osteoarthritis by
studying finger joints [99,100]. Yet all those studies are in an early exploratory phase. Substantial
efforts are required to develop these methods into clinical diagnostic tools suited for screening
purposes, with applications in breast cancer being the most advanced. Another clinical application
of optical imaging is the assessment of brain function/brain oxygenation in neonates or even adults.
Yet this approach has only limited connections to fluorescence optical imaging as it is based on
spectroscopic analysis of hemoglobin and oxyhemoglobin signals, which are described elsewhere
[167–169].
The use of fluorescence approaches in clinics is very limited due to the lack of clinically approved
fluorescent probes. Therefore translation of preclinical optical imaging approaches might consist
of translating a preclinical optical into a clinical nuclear imaging readout. An example might be
the use of plaque-specific dyes in preclinical studies of mouse models of Alzheimer’s disease and
of PET probes such as Pittsburgh compound B (PIB) for the corresponding clinical application.
A strategic clinical application domain for which fluorescence imaging appears highly attractive
is surgery. Realtime imaging might guide the surgeon in identifying the margins of malignant
tissue, which will fluoresce during illumination with an appropriate wavelength to support
dissection, when using tumor specific fluorescent markers. The high demands on speed and the
fact that superficial information is required only renders planar imaging the method of choice.
The feasibility of imaging large human organs was demonstrated by Ntziachristos et al. [170]
with simulation studies, from which the authors concluded that critical for accurate tissue
identification is a high fluorescence TBR rather than limitation imposed by light propagation
in tissue. While optical imaging is attractive for exposed single organs during surgery, it is not
possible to image these organs in their natural location several centimeters below the surface and
embedded within other tissue layers. Under these circumstances photon propagation becomes the
limiting factor, which narrow down potential applications to low absorptive (e.g., adipose tissue,
breast) and superficial (e.g., surgically exposed) tissue.
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Thus, regarding clinical application optical imaging is covering potentially important niches for
routinely clinical use.
6. Conclusions and Future Directions
Fluorescence imaging is a powerful tool for non-invasive investigation of biomedical systems
at the molecular level. The targeted probes for optical imaging are easy to handle, widely
available and do not require radiation protection measures as for probes involving radionuclides.
In particular, FMT enabling to derive quantitative information form three-dimensional data sets
is of interest for different biomedical research areas including pharmaceutical research.
FMT development is towards 360◦ whole body animal scanners which allows to freely select
one or several regions of interest without need for moving the animal. Forward modeling will
be further improved by incorporation of more realistic heterogeneous tissue models using either
morphology standardized tissue layers that has to be adapted to a specific problem or alternatively
the actual anatomical features of the object under study derived from a hybrid experiment.
This requires combining FMT with structural imaging such as CT or MRI, a major direction of
instrumental development. Even though CT provides sufficient contrast for identification of organ
boundaries, MRI is superior in imaging soft tissue. Including anatomical constraints provided by
these modalities in the reconstruction process will considerably improve the spatial accuracy of the
reconstructed objects. Nevertheless, care has to be taken to not over constrain the outcome of the
reconstruction, which would bias the interpretation of the results. Comprehensive understanding
of biological processes is based on complementary information of structural functional and/or
molecular nature.
Fully integrated solutions for simultaneous imaging are technically more demanding but
offer substantial advantages such as inherent registration and the ability to monitor processes
simultaneously. This translates into instrument design: FMT scanners are being developed as
inserts to commercially available MRI scanners or mounted to the gantry of a CT scanner for
full 360◦ space coverage. It is foreseeable that future high end FMT systems always designed
as hybrids.
A key success factor for molecular imaging is the design of sensitive reporter systems.
Developments are towards probes with better optical properties, i.e., excitation and emission
wavelength in the proper wavelength domain, higher sensitivity, i.e., probes with better fluorescent
quantum yield, smart probes to improve the target-to-background contrast. Similar to drug like
molecules, target delivery might be an issue, in particular when targeting intramolecular targets.
Sensitive detection devices providing quantitative information on molecular processes in the
intact organism are of high interest for basic biomedical research and in particular for therapy
development. Molecular information is central for target validation, for pharmacokinetic studies,
to demonstrate the pharmacological proof of principle (e.g., does a compound reach its target
and inhibit the enzyme activity, Figure 6) and eventually can be used as a biomarker of
compound efficacy. The translational potential of optical imaging is limited due to constraints
regarding photon propagation in tissue, exceptions being breast imaging or intraoperative imaging.
Nevertheless, the concept developed using fluorescent readouts in experimental animals might be
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translated into the clinics by replacing the fluorescent reporter by a radionuclide probe. This
perspective renders optical imaging an attractive tool for pharmaceutical researchers both in view
of experimental research and translation applications.
Acknowledgements
We all acknowledge Swiss National Foundation under Grant SNF 3100-112835 and Grant
310030-126029 and FMT-XCT EU FP7 Grant. J.R. acknowledges the Bill and Melinda
Gates Foundation.
References
1. Ntziachristos, V.; Tung, C.H.; Bremer, C.; Weissleder, R. Fluorescence molecular
tomography resolves protease activity in vivo. Nat. Med. 2002, 8, 757–760.
2. Ntziachristos, V.; Weissleder, R. Charge-coupled-device based scanner for tomography of
fluorescent near-infrared probes in turbid media. Med. Phys. 2002, 29, 803–809.
3. Boas, D.A.; Brooks, D.H.; Miller, E.L.; DiMarzio, C.A.; Kilmer, M.; Gaudette, R.J.; Zhang,
Q. Imaging the Body with Diffuse Optical Tomography. IEEE Signal Process. Mag.
2001, 57–75.
4. Corlu, A.; Choe, R.; Durduran, T.; Rosen, M.A.; Schweiger, M.; Arridge, S.R.; Schnall,
M.D.; Yodh, A.G. Three-dimensional in vivo fluorescence diffuse optical tomography of
breast cancer in humans. Opt. Express 2007, 15, 6696–6716.
5. Ntziachristos, V.; Yodh, A.G.; Schnall, M.; Chance, B. Concurrent MRI and diffuse optical
tomography of breast after indocyanine green enhancement. Proc. Natl. Acad. Sci. USA
2000, 97, 276–2772.
6. Antcliff, R.J.; Stanford, M.R.; Chauhan, D.S.; Graham, E.M.; Spalton, D.J.; Shilling, J.S.;
Ffytche, T.J.; Marshall, J. Comparison between optical coherence tomography and fundus
fluorescein angiography for the detection of cystoid macular edema in patients with uveitis.
Ophthalmology 2000, 107, 593–599.
7. Ishimaru, A. Wave Propagation and Scattering in Random Media; Oxford University Press:
Oxford, UK, 1997.
8. Arridge, S.R. Optical tomography in medical imaging. Inverse Probl. 1999, 15, R41–R93.
9. Yoo, K.M.; Liu, F.; Alfano, R.R. When does the diffusion approximation fail to describe
photon transport in random media? Phys. Rev. Lett. 1990, 64, 2647–2650.
10. Li, X.; Chance, B.; Yodh, A.G. Fluorescent heterogeneities in turbid media: limits
for detection, charcterization, and comparison with absorption. Appl. Opt. 1998,
37, 6833–6844.
11. O’Leary, M.; Boas, D.; Li, X.; Chance, B.; Yodh, A. Fluorescence lifetime imaging in turbid
media. Opt. Lett. 1996, 21, 158–160.
12. Li, X.D.; O’Leary, M.A.; Boas, D.A.; Chance, B.; Yodh, A.G. Fluorescent diffuse photon
density waves in homogeneous and heterogeneous turbid media: Analytic solutions and
applications. Appl. Opt. 1996, 35, 3746–3758.
Pharmaceutics 2011, 3 264
13. Kienle, A.; Patterson, M.S. Improved solutions of the steady-state and the time-resolved
diffusion equation for reflectance from a semi-infinite turbid medium. J. Opt. Soc. Am. A
1997, 14, 246–254.
14. Patterson, M.S.; Chance, B.; Wilson, B.C. Time resolved reflectance and transmittance for
the noninvasive measurement of tissue optical properties. Appl. Opt. 1989, 28, 2331–2336.
15. van der Mark, M.B.; van Albada, M.P.; Lagendijk, A. Light scattering in strongly scattering
media: multiple scattering and weak localization. Phys. Rev. B 1988, 37, 3575–3592.
16. Ripoll, J.; Ntziachristos, V.; Culver, J.P.; Pattanayak, D.N.; Yodh, A.G.; Nieto-Vesperinas,
M. Recovery of optical parameters in multiple-layered diffusive media: theory and
experiments. J. Opt. Soc. Am. A 2001, 18, 821–830.
17. Martelli, F.; Sassaroli, A.; Yamada, Y.; Zaccanti, G. Analytical approximate solution of the
time domain diffusion equation in layered slabs. J. Opt. Soc. Am. A 2002, 19, 71–80.
18. Kienle, A. Light diffusion through a turbid parallelepiped. J. Opt. Soc. Am. A 2005,
22, 1883–1888.
19. Walker, S.A.; Boas, D.A.; Gratton, E. Photon density waves scattered from cylindrical
inhomogeneities: theory and experiments. Appl. Opt. 1998, 37, 1935–1944.
20. Liemert, A.; Kienle, A. Light diffusion in a turbid cylinder. II. Layered case. Opt. Express
2010, 18, 9266–9279.
21. Boas, D.A.; O’Leary, M.A.; Chance, B.; Yodh, A.G. Scattering of diffuse density waves by
spherical inhomogeneities within turbid media: Analytic solution and applications. Proc.
Natl. Acad. Sci. USA 1994, 91, 4887–4891.
22. Arridge, S.R.; Cope, M.; Delpy, D.T. The theoretical basis for the determination of
optical pathlengths in tissue: temporal and frequency analysis. Phys. Med. Biol. 1992,
37, 1531–1560.
23. Ripoll, J.; Nieto-Vesperinas, M. Scattering integral equation for diffusive waves: detection
of objects buried in diffusive media in the presence of rough interfaces. J. Opt. Soc. Am.
A 1999, 16, 1453–1465.
24. Gibson, A.P.; Hebden, J.C.; Arridge, S.R. Recent advances in diffuse optical imaging. Phys.
Med. Biol. 2005, 50, R1–R43.
25. Ntziachristos, V.; Weissleder, R. Experimental three-dimensional fluorescence
reconstruction of diffuse media by use of a normalized Born approximation. Opt. Lett.
2001, 26, 893–895.
26. Soubret, A.; Ripoll, J.; Ntziachristos, V. Accuracy of fluorescent tomography in the presence
of heterogeneities: Study of the normalized Born ratio. IEEE Trans. Med. Imaging 2005,
24, 1377–1386.
27. Roy, R.; Godavarty, A.; Sevick-Muraca, E.M. Fluorescence-enhanced optical tomography
using referenced measurements of heterogeneous media. IEEE Trans. Med. Imaging 2003,
22, 824–836.
28. Kak, A.C.; Slaney, M. Principles of Computerized Tomographic Imaging; Society of
Industrial and Applied Mathematics: Philadelphia, PA, USA, 2001.
Pharmaceutics 2011, 3 265
29. Gaudette, R.J.; Brooks, D.H.; DiMarzi, C.A.; Kilmer, M.E.; Miller, E.L.; Boas, D.A. A
comparison study of linear reconstruction techniques for diffuse optical tomographic imaging
of absorption coefficient. Phys. Med. Biol. 2000, 45, 1051–1070.
30. Arridge, S.R.; Schotland, J.C. Optical tomography: forward and inverse problems. Inverse
Probl. 2009, 25, 123010.
31. Shaner, N.C.; Steinbach, P.A.; Tsien, R.Y. A guide to choosing fluorescent proteins. Nat.
Methods 2005, 2, 905–909.
32. Tsien, R.Y. Building and breeding molecules to spy on cells and tumors. FEBS Lett. 2005,
579, 927–932.
33. Chatterjeea, D.K.; Rufaihaha, A.J.; Zhanga, Y. Upconversion fluorescence imaging of cells
and small animals using lanthanide doped nanocrystals. Biomaterials 2008, 29, 937–943.
34. Zhou, J.; sun, Y.; Du, X.; Xiong, L.; Hu, H.; Liuzzi, F. Dual-modality in vivo imaging
using rare-earth nanocrystals with near-infrared to near-infrared (NIR-to-NIR) upconversion
luminescence and magnetic resonance properties. Biomaterials 2010, 31, 3287–3295.
35. Nyk, M.; Kumar, R.; Ohulchanskyy, T.Y.; Bergey, E.J.; Prasad, P.N. High contrast in vitro
and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion
in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett. 2008, 8, 3834–3838.
36. Tian, Y.; Cao, W.H.; Luo, X.X.; Fu, Y. Preparation and luminescence property of
Gd2O2S:Tb X-ray nano-phosphors using the complex precipitation method. J. Alloys
Compounds 2007, 433, 313–317.
37. Wang, H.; Wang, R.; Sun, X.; Yan, R.; Li, Y. Synthesis of red-luminescent Eu3+ doped
lanthanides compounds hollow spheres. Mater. Res. Bull. 2005, 40, 911–919.
38. Bremer, C.; Tung, C.H.; Weissleder, R. In vivo molecular target assessment of matrix
metalloproteinase inhibition. Nat. Med. 2001, 7, 743–748.
39. Tung, C.H.; Mahmood, U.; Bredow, S.; Weissleder, R. In vivo imaging of proteolytic enzyme
activity using a novel molecular reporter. Cancer Res. 2000, 60, 4953–4958.
40. Kobayashi, H.; Ogawa, M.; Alford, R.; Choyke, P.L.; Urano, Y. New strategies for fluorescent
probe design in medical diagnostic imaging. Chem. Rev. 2010, 110, 2620–2640.
41. Han, J.; Burgess, K. Fluorescent indicators for intracellular pH. Chem. Rev. 2010,
110, 2709–2728.
42. Bünzli, J.C. Lanthanide luminescence for biomedical analyses and imaging. Chem. Rev.
2010, 110, 2729–2755.
43. Sevick-Muraca, E.M.; Houston, J.P.; Gurfinkel, M. Fluorescence-enhanced, near infrared
diagnostic imaging with contrast agents. Curr. Opin. Chem. Biol. 2002, 6, 642–650.
44. Mahmood, U.; Tung, C.H.; Bogdanov, A.; Weissleder, R. Near-infrared optical imaging of
protease activity for tumor detection. Radiology 1999, 213, 866–870.
45. Ke, S.; Wen, X.; Gurfinkel, M.; Charnsangavej, C.; Wallace, S.; Sevick-Muraca, E.M.;
Li, C. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer
xenografts. Cancer Res. 2003, 63, 7870–7875.
46. Weissleder, R.; Tung, C.H.; Mahmood, U.; Bogdanov, A. In vivo imaging of tumors with
protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 1999, 17, 375–378.
Pharmaceutics 2011, 3 266
47. Wunder, A.; Tung, C.H.; Müller-Ladner, U.; Weissleder, R.; Mahmood, U. In vivo imaging of
protease activity in arthritis: A novel approach for monitoring treatment response. Arthritis
Rheum. 2004, 50, 2459–2465.
48. Zaheer, A.; Lenkinski, R.E.; Mahmood, A.; Jones, A.G.; Cantley, L.C.; Frangioni, J.V. In
vivo near-infrared fluorescence imaging of osteoblastic activity. Nat. Biotechnol. 2001,
19, 1148–1154.
49. Yang, M.; Baranov, E.; Jiang, P.; Sun, F.X.; Li, X.M.; Hasegawa, S.; Bouvet, M.;
Al-Tuwaijri, M.; Chishima, T.; Shimada, H.; Moossa, A.R.; Penman, S.; Hoffman, R.M.
Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases.
Proc. Natl. Acad. Sci. USA 2000, 97, 1206–1211.
50. Ntziachristos, V. Fluorescence molecular imaging. Annu. Rev. Biomed. Eng. 2006,
8, 1–33.
51. Cutler, M. Transillumination as an aid in the diagnosis of breast lesions. Surg. Gynecol.
Obstet. 1929, 8, 721–729.
52. Ntziachristos, V.; Turner, G.; Dunham, J.; Windsor, S.; Soubret, A.; Ripoll, J.; Shih, H.A.
Planar fluorescence imaging using normalized data. J. Biomed. Opt. 2005, 10, 064007.
53. Farkas, D.L.; Du, C.; Fisher, G.W.; Lau, C.; Niu, W.; Wachman, E.S.; Levenson, R.M.
Non-invasive image acquisition and advanced processing in optical and bioimaging. Comput.
Med. Imaging Graph. 1998, 22, 89–102.
54. Gao, X.; Cui, Y.; Levenson, R.M.; Chung, L.W.K.; Nie, S. In vivo cancer targeting and
imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22, 969–976.
55. Ntziachristos, V.; Ripoll, J.; Wang, L.V.; Weissleder, R. Looking and listening to light: the
evolution of whole-body photonic imaging. Nat. Biotechnol. 2005, 23, 313–320.
56. Hielscher, A.H. Optical tomographic imaging of small animals. Curr. Opin. Biotechnol.
2005, 16, 79–88.
57. Leblond, F.; Davis, S.C.; Valdés, P.A.; Pogue, B.W. Pre-clinical whole-body fluorescence
imaging: Review of instruments, methods and applications. J. Photochem. Photobiol. B:
Biol. 2010, 98, 77–94.
58. Turner, G.M.; Zacharakis, G.; Soubret, A.; Ripoll, J.; Ntziachristos, V. Complete-angle
diffuse optical tomography by use of early photons. Opt. Lett. 2005, 30, 409–411.
59. Niedre, M.J.; de Kleine, R.H.; Aikawa, E.; Kirsch, D.G.; Weissleder, R.; Ntziachristos,
V. Early photon tomography allows fluorescence detection of lung carcinomas and disease
progression in mice in vivo. Proc. Natl. Acad. Sci. USA 2008, 105, 19126–19131.
60. Ntziachristos, V.; Ma, X.; Chance, B. Time-correlated single photon counting imager for
simultaneous magnetic resonance and near-infrared mammography. Rev. Sci. Instrum.
1998, 69, 4221–4233.
61. Culver, J.P.; Ntziachristos, V.; Holboke, M.J.; Yodh, A.G. Optimization of optode
arrangements for diffuse optical tomography: A singular-value analysis. Opt. Lett. 2001,
26, 701–703.
62. Culver, J.P.; Choe, R.; Holboke, M.J.; Zubkov, L.; Durduran, T.; Slemp, A.; Ntziachristos,
V.; Chance, B.; Yodh, A.G. Three-dimensional diffuse optical tomography in the parallel
Pharmaceutics 2011, 3 267
plane transmission geometry: Evaluation of a hybrid frequency domain/continuous wave
clinical system for breast imaging. Med. Phys. 2003, 30, 235–247.
63. Graves, E.E.; Ripoll, J.; Weissleder, R.; Ntziachristos, V. A submilimeter resolution
fluorescence molecular imaging system for small animal imaging. Med. Phys. 2003,
30, 901–911.
64. Zacharakis, G.; Ripoll, J.; Weissleder, R.; Ntziachristos, V. Fluorescent protein tomography
scanner for small animal imaging. IEEE Trans. Med. Imaging 2005, 24, 878–886.
65. Schulz, R.B.; Ripoll, J.; Ntziachristos, V. Experimental fluorescence tomography of tissues
with noncontact measurements. IEEE Trans. Med. Imaging 2004, 23, 492–500.
66. Ripoll, J.; Schulz, R.B.; Ntziachristos, V. Free-space propagation of diffuse light: Theory
and experiments. Phys. Rev. Lett. 2003, 91, 103901.
67. Schulz, R.B.; Ripoll, J.; Ntziachristos, V. Noncontact optical tomography of turbid media.
Opt. Lett. 2003, 28, 1701–1703.
68. Martin, A.; Aguirre, J.; Sarasa-Renedo, A.; Tsoukatou, D.; Garofalakis, A.; Meyer, H.;
Ripoll, J.; Planas, A.M. Imaging changes in lymphoid organs in vivo after brain ischemia
with three-dimensional fluorescence molecular tomography in transgenic mice expressing
green fluorescent protein in T lymphocytes. Mol. Imaging 2008, 7, 1–11.
69. Koenig, A.; Hervé, L.; Josserand, V.; Berger, M.; Boutet, J.; Silva, A.D.; Dinten, J.M.;
Peltié, P. In vivo mice lung tumor follow-up with fluorescence diffuse optical tomography.
J. Biomed. Opt. 2008, 13, 011008.
70. Meyer, H.; Garofalakis, A.; Zacharakis, G.; Psycharakis, S.; Mamalaki, C.; Kioussis, D.;
Economou, E.N.; Ntziachristos, V.; Ripoll, J. Non-contact optical imaging in mice with full
angular coverage and automatic surface extraction. Appl. Opt. 2007, 46, 3617–3627.
71. Deliolanis, N.; Lasser, T.; Hyde, D.; Soubret, A.; Ripoll, J.; Ntziachristos, V. Free-space
fluorescence molecular tomography utilizing 360◦ geometry projections. Opt. Lett. 2007,
32, 382–384.
72. Lasser, T.; Soubret, A.; Ripoll, J.; Ntziachristos, V. Surface reconstruction for free-space
360circ fluorescence molecular tomography and the effects of animal motion. IEEE Trans.
Med. Imaging 2008, 27, 188–194.
73. Li, C.; Mitchell, G.S.; Dutta, J.; Ahn, S.; Leahy, R.M.; Cherry, S.R. A three-dimensional
multispectral fluorescence optical tomography imaging system for small animals based on a
conical mirror design. Opt. Express 2099, 17, 7571–7578.
74. Siegel, A.M.; Mandeville, J.B.; Boas, D.A. Temporal comparison of functional brain imaging
with optical tomography and fMRI during rat forepaw stimulation. Phys. Med. Biol. 2003,
48, 1391–1403.
75. McCann, C.M.; Waterman, P.; Figueiredo, J.L.; Aikawa, E.; Weissleder, R.; Chen, J.W.
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals
glioma response to chemotherapy. Neuroimage 2009, 45, 360–369.
76. Nahrendorf, M.; Waterman, P.; Thurber, G.; Groves, K.; Rajopadhye, M.; Panizzi, P.;
Marinelli, B.; Aikawa, E.; Pittet, M.J.; Swirski, F.K.; Weissleder, R. Hybrid in vivo
Pharmaceutics 2011, 3 268
FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors.
Artheroscler. Thromb. Vasc. Biol. 2009, 29, 1441–1451.
77. Allard, M.; Côté, D.; Davidson, L.; Dazai, J.; Henkelman, R.M. Combined magnetic
resonance and bioluminescence imaging of live mice. J. Biomed. Opt. 2007, 12, 034018.
78. Celentano, L.; Laccetti, P.; Liuzzi, R.; Mettivier, G.; Montesi, M.C.; Autiero, M.; Riccio,
P.; Roberti, G.; Russo, P.; Salvatore, M. Preliminary tests of a prototype system for optical
and radionuclide imaging in small animals. IEEE Trans. Nucl. Sci. 2003, 50, 1693–1701.
79. Autiero, M.; Celentano, L.; Cozzolino, R.; Laccetti, P.; Marotta, M.; Mettivier, G.; Montesi,
M.C.; Riccio, P.; Roberti, G.; Russo, P. Experimental study on in vivo optical and
radionuclide imaging in small animals. IEEE Trans. Nucl. Sci. 2005, 52, 205–209.
80. Joshi, A.; Rasmussen, J.C.; Kwon, S.; Wareing, T.A.; McGhee, J.; Sevick-Muraca, E.M.
Multi-modality CT-PET-NIR fluorescence tomography. In Proceedings of 2008 5th IEEE
international symposium on biomedical imaging: From nano to macro, Paris, France, 14-17
May 2008.
81. Deroose, C.M.; De, A.; Loening, A.M.; Chow, P.L.; Ray, P.; amd, S.S.; Gambhir,
A.F.C. Multimodality imaging of tumor xenografts and metastases in mice with combined
small-animal PET, small-animal CT, and bioluminescence imaging. J. Nucl. Med. 2007,
48, 295–303.
82. Ale, A.; Schulz, R.B.; Sarantopoulos, A.; Ntziachristos, V. Imaging performance of a hybrid
X-ray computed tomography-fluorescence tomography system using priors. Med. Phys.
2010, 37, 1976–1986.
83. Zacharakis, G.; Kambara, H.; Shih, H.; Ripoll, J.; Grimm, J.; Saeki, Y.; Weissleder, R.;
Ntziachristos, V. Volumetric tomography of fluorescent proteins through small animals in
vivo. Proc. Natl. Acad. Sci. USA 2005, 102, 18252–18257.
84. Licha, K.; Lin, C.P. Dual-modality molecular imaging for small animals using fluorescence
and X-ray computed tomography, Molecular Imaging II. Proc. Soc. Photo-Opt. Instrum.
Eng. 2009, 7370, 73700G-73700G-6.
85. Hintersteiner, M.; Enz, A.; Frey, P.; Jaton, A.L.; Kinzy, W.; Kneuer, R.; Neumann, U.;
Rudin, M.; Staufenbiel, M.; Stoeckli, M.; Wiederhold, K.H.; Gremlich, H.U. In vivo
detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe.
Nat. Biotechnol. 2005, 23, 577–583.
86. Hyde, D.; de Kleine, R.; MacLaurin, S.A.; Miller, E.; Brooks, D.H.; Krucker, T.;
Ntziachristos, V. Hybrid FMT-CT imaging of amyloid-β plaques in a murine Alzheimer’s
disease model. Neuroimage 2009, 44, 1304–1311.
87. Kepshire, D.; Mincu, N.; Hutchins, M.; Gruber, J.; Dehghani, H.; Hypnarowski, J.; Leblond,
F.; Khayat, M.; Pogue, B.W. A microcomputed tomography guided fluorescence tomography
system for small animal molecular imaging. Rev. Sci. Instrum. 2009, 80, 043701.
88. Barber, W.C.; Lin, Y.; Nalcioglu, O.; Iwanczyk, J.S.; Hartsough, N.E.; Gulsen, G. Combined
fluorescence and X-ray tomography for quantitative in vivo detection of fluorophore. Tech.
Canc. Res. Treat. 2010, 9, 45–52.
Pharmaceutics 2011, 3 269
89. Lin, Y.; Barber, W.C.; Iwanczyk, J.S.; Roeck, W.; Nalcioglu, O.; Gulsen, G. Quantiative
fluorescence tomography using a combined tri-modality FT/DOT/XCT system. Opt.
Express 2010, 18, 7835–7850.
90. Lin, Y.; Barber, W.C.; Iwanczyk, J.S.; Roeck, W.W.; Nalcioglu, O.; Gulsen, G. Quantiative
fluorescence tomography using a trimodality system: in vivo validation. J. Biomed. Opt.
Lett. 2010, 15, 040503.
91. Schulz, R.B.; Ale, A.; Sarantopoulos, A.; Freyer, M.; Soehngen, E.; Zientkowska, M.;
Ntziachristos, V. Hybrid system for simultaneous fluorescence and X-ray computed
tomography. IEEE Trans. Med. Imaging 2010, 29, 465–473.
92. Licha, K.; Lin, C.P. Hybrid fluorescence tomography/X-ray tomography improves
reconstruction quality, Molecular Imaging II. Proc. Soc. Photo-Opt. Instrum. Eng. 2009,
7370, 73700H-73700H-4.
93. Yang, X.; Gong, H.; Quan, G.; Deng, Y.; Luo, Q. Combined system of fluorescence diffuse
optical tomography and microcomputed tomography for small animal imaging. Rev. Sci.
Instrum. 2010, 81, 054304.
94. da Silva, A.; Leabad, M.; Bordy, T.; Dinten, J.M.; Peltié, P.; Rizo, P. Design of a small
animal multimodality tomographer for x-ray and optical coupling: Theory and experiments.
Nucl. Instr. Meth. Phys. Res. A 2007, 571, 118–121.
95. Silva, A.D.; Leabad, M.; Driol, C.; Bordy, T.; Debourdeau, M.; Dinten, J.M.; Peltié, P.;
Rizo, P. Optical calibration protocol for an x-ray and optical multimodality tomography
system dedicated to small-animal examination. Appl. Opt. 2009, 48, D151–D162.
96. Liu, J.; Wang, Y.; Qu, X.; Li, X.; Ma, X.; Han, R.; Hu, Z.; Chen, X.; Sun, D.; Zhang,
R.; Chen, D.; Chen, D.; Chen, X.; Liang, J.; Cao, F.; Tian, J. In vivo quantitative
bioluminescence tomography using heterogeneous and homogeneous mouse models. Opt.
Express 2010, 18, 13102–13113.
97. Zhang, Q.; Brukillacchio, T.J.; Li, A.; Stott, J.J.; Chaves, T.; Hillman, E.; Wu, T.;
Chorloton, M.; Rafferty, E.; Moore, R.H.; Kopans, D.B.; Boas, D.A. Coregistered
tomographic x-ray and optical breast imaging: initial results. J. Biomed. Opt. 2005,
10, 024033.
98. Li, A.; Miller, E.L.; Kilmer, M.E.; Brukilacchio, T.J.; Chaves, T.; Stott, J.; Zhang, Q.;
Wu, T.; Chorlton, M.; Moore, R.H.; Kopans, D.B.; Boas, D.A. Tomographic optical breast
imaging guided by three-dimensional mammography. Appl. Opt. 2003, 42, 5181–5190.
99. Yuan, Z.; Zhang, Q.; Sobel, E.; Jiang, H. Three-dimensional diffuse optical tomography of
osteoarthritis: initial results in the finger joints. J. Biomed. Opt. 2007, 12, 034001.
100. Yuan, Z.; Zhang, Q.; Sobel, E.S.; Jiang, H. Tomographic X-ray-guided three-dimensional
diffuse optical tomography of osteoarthritis in the finger joints. J. Biomed. Opt. 2008,
13, 044006.
101. Carpenter, C.M.; Sun, C.; Pratx, G.; Rao, R.; Xing, L. Hybrid X-ray/optical luminescence
imaging: Characterization of experimental conditions. Med. Phys. 2010, 37, 4011–4018.
102. Pratx, G.; Carpenter, C.M.; Sun, C.; Xing, L. X-ray luminescence computed tomography via
selective excitation: A feasibility study. IEEE Trans. Med. Imaging 2010, 29, 1992–1999.
Pharmaceutics 2011, 3 270
103. Davis, S.C.; Samkoe, K.S.; O’Hara, J.A.; Gibbs-Strauss, S.L.; Paulsen, K.D.; Pogue,
B.W. Comparing implementations of magnetic-resonance-guided fluorescence molecular
tomography for diagnostic classification of brain tumors. J. Biomed. Opt. 2010, 15, 051602.
104. Tromberg, B.J.; Pogue, B.W.; Paulsen, K.D.; Yodh, A.G.; Boas, D.A.; Cerussi, A.E.
Assessing the future of diffuse optical imaging technologies for breast cancer managment.
Med. Phys. 2008, 35, 2443–2451.
105. Azar, F.S.; Intes, X. MRI-guided fluorescence tomography of the breast: A phantom
study, Multimodel Biomedical Imaging IV. Proc. Soc. Photo-Opt. Instrum. Eng. 2009,
7171, 71710I.
106. Davis, S.C.; Dehghani, H.; Wang, J.; Jiang, S.; Pogue, B.W.; Paulsen, K.D. Image-guided
diffuse optical fluorescence tomography implemented with Laplacian-type regularization.
Opt. Express 2007, 15, 4066–4082.
107. Davis, S.C.; Pogue, B.W.; Springett, R.; Leussler, C.; Mazurkewitz, P.; Tuttle, S.B.;
Gibbs-Strauss, S.L.; Jiang, S.S.; Dehghani, H.; Paulsen, K.D. Magnetic resonance-coupled
tomography scanner for molecular imaging of tissue. Rev. Sci. Instrum. 2008, 79, 064302.
108. Azar, F.S.; Intes, X. MRI-coupled spectrally-resolved fluorescence tomography for in vivo
imaging. Proc. Soc. Photo-Opt. Instrum. Eng. 2008, 6850, 68500K-68500K-9.
109. Davis, S.C.; Samkoe, K.S.; O’Hara, J.A.; Gibbs-Strauss, S.L.; Payne, H.L.; Hoopes,
J.; Paulsen, K.D.; Pogue, B.W. MRI-coupled fluorescence tomography quantifies EGFR
activity in brain tumor. Acad. Radiol. 2010, 17, 271–276.
110. Xu, H.; Springet, R.; Dehghani, H.; Pogue, B.W.; Paulsen, K.D.; Dunn, J.F.
Magentic-resonance-imaging-coupled broadband near-infrared tomography system for small
animal brain studies. Appl. Opt. 2005, 44, 2177–2188.
111. Gulsen, G.; Birgul, O.; Unlu, M.B.; Shafiiha, R.; Nalcioglu, O. Combined diffuse optical
tomography (DOT) and MRI system for cancer imaging in small animals. Tech. Canc.
Res. Treat. 2006, 5, 351–363.
112. Zhang, X.; Toronov, V.Y.; Webb, A.G. Simultaneous integrated diffuse optical tomography
and functional magnetic resonance imaging of the human brain. Opt. Express 2005,
13, 5513–5521.
113. Huppert, T.J.; Diamond, S.G.; Boas, D.A. Direct estimation of evoked hemoglobin changes
by multimodality fusion imaging. J. Biomed. Opt. 2008, 13, 054031.
114. Ntziachristos, V. Going deeper than microscopy: optical imaging frontier in biology. Nat.
Methods 2010, 7, 603.
115. Razansky, D.; Distel, M.; Vinegoni, C.; Perrimon, N.; Köster, R.W.; Ntziachristos, V.
Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nat.
Photon. 2009, 3, 412–417.
116. Boutet, J.; Hervé, L.; Debourdeau, M.; Guyon, L.; Peltié, P.; Dinten, J.M.; Saroul, L.;
Duboeuf, F.; Vray, D. Bimodal ultrasound and fluorescence approach for prostate cancer
diagnosis. J. Biomed. Opt. 2009, 14, 064001.
Pharmaceutics 2011, 3 271
117. Holboke, M.J.; Tromberg, B.J.; Li, X.; Shah, N.; Fishkin, J.; Kidney, D.; Butler, J.;
Chance, B.; Yodh, A.G. Three-dimensional diffuse optical mammography with ultrasound
localization in human subject. J. Biomed. Opt. 2000, 5, 237–247.
118. Zhu, Q.; Durduran, T.; Ntziachristos, V.; Holboke, M.; Yodh, A.G. Imager that combines
near-infrared diffuse light and ultrasound. Opt. Lett. 1999, 24, 1050–1052.
119. Zhu, Q.; Chen, N.; Kurtzman, S.H. Imaging tumor angiogenesis by use of combined
near-infrared diffuse light and ultrasound. Opt. Lett. 2003, 28, 337–339.
120. Xu, G.; Piao, D.; Musgrove, C.H.; Bunting, C.F.; Dehghani, H. Trans-rectal
ultrasound-coupled near-infrared optical tomography of prostate Part I: Simulation. Opt.
Express 2008, 16, 17484–17504.
121. Jiang, Z.; Piao, D.; Xu, G.; Ritchey, J.W.; Holoyoak, G.R.; Bartels, K.E.; Bunting,
C.F.; Slobodov, G.; Krasinki, J.S. Trans-rectal ultrasound-coupled near-infrared optical
tomography of the prostate Part II: Experimental demonstration. Opt. Express 2008,
16, 17505–17520.
122. Jiang, Z.; Holyoak, G.R.; Bartels, K.E.; Ritchey, J.W.; Xu, G.; Bunting, C.R.; Slobodov,
G.; Piao, D. In vivo trans-rectal ultrasound-coupled optical tomography of a transmissible
venereal tumor model in the canine pelvic canal. J. Biomed. Opt. 2009, 14, 030506.
123. Culver, J.; Akers, W.; Achilefu, S. Multimodality molecular imaging with combined optical
and SPECT/PET modalities. J. Nucl. Med. 2008, 49, 169–172.
124. Prout, D.L.; Silverman, R.W.; Chatziioannou, A. Detector concept for OPET, a combined
PET and optical imaging system. IEEE Trans. Nucl. Sci. 2004, 51, 752–756.
125. Jung, J.H.; Choi, Y.; Hong, K.J.; Min, B.J.; Choe, J.Y.C.Y.S.; Lee, K.H.; Kim, B.T.
Development of a dual modality imaging system: a combined gamma camera and optical
imager. Phys. Med. Biol. 2009, 54, 4547–4559.
126. Prout, D.L.; Silverman, R.W.; Chatziioannou, A. Readout of the optical PET (OPET)
detector. IEEE Trans. Nucl. Sci. 2005, 52, 28–32.
127. Douraghy, A.; Rannou, F.R.; Silverman, R.W.; Chatziioannou, A.F. FPGA electronics for
OPET: A dual-modality optical and positron emission tomograph. IEEE Trans. Nucl. Sci.
2008, 55, 2541–2545.
128. Vu, N.T.; Silverman, R.W.; Chatziioannou, A.F. Preliminary performance of optical PET
(OPET) detectors for the detection of visible light photons. Nucl. Instrum. Meth Phys.
Res. A 2006, 569, 563–566.
129. Alexandrakis, G.; Rannou, F.R.; Chatziioannou, A.F. Tomographic bioluminescence
imaging by use of a combined optical-PET (OPET) system: a computer simulation
feasibility study. Phys. Med. Biol. 2005, 50, 4225–4241.
130. Alexandrakis, G.; Rannou, F.R.; Chatziioannou, A.F. Effect of optical properties estimation
accuracy on tomographic bioluminescence imaging: Simulation of a combined optical-PET
(OPET) system. Phys. Med. Biol. 2006, 51, 2045–2053.
131. Rannou, F.R.; Kohli, V.; Prout, D.L.; Chatziioannou, A.F. Investigation of OPET
performance using GATE a geant4-based simulation software. IEEE Trans. Nucl. Sci.
2004, 51, 2713–2717.
Pharmaceutics 2011, 3 272
132. Douraghy, A.; Prout, D.L.; Silverman, R.W.; Chatziioannou, A.F. Evaluation of scintillator
afterglow for use in a combined optical and PET imaging tomograph. Nucl. Instrum. Meth.
Phys. Res. A 2006, 569, 557–562.
133. Peter, J.; Unholtz, D.; Schulz, R.B.; Semmler, W. Development and initial results of a
tomographic dual-modality positron/optical small animal imager. IEEE Trans. Nucl. Sci.
2007, 54, 1553–1560.
134. Nahrendorf, M.; Keliher, E.; Marinelli, B.; Waterman, P.; Feruglio, P.F.; Fexon, L.;
Pivovarov, M.; Swirski, F.K.; Pittet, M.J.; Vinegoni, C.; Weissleder, R. Hybrid PET-optical
imaging using targeted probes. Proc. Natl. Acad. Sci. USA 2010, 107, 7910–7915.
135. Garofalakis, A.; Dubois, A.; Kühnast, B.; Dupont, D.M.; Janssens, I.; Mackiewicz, N.; Dollé,
F.; Tavitian, B.; Ducongé, F. In vivo validation of free-space fluorescence tomography using
nuclear imaging. Opt. Lett. 2010, 35, 3024–3026.
136. Robertson, R.; Germanos, M.S.; Li, C.; Mitchell, G.S.; Cherry, S.R.; Silva, M.D. Optical
imaging of Cerenkov light generation from positron-emitting radiotracers. Phys. Med. Biol.
2009, 54, N355–N365.
137. Liu, H.; Ren, G.; Miao, Z.; Zhang, X.; Tang, X.; Han, P.; Gambhir, S.S.; Cheng, Z.
Molecular optical imaging with radioactive probes. PLoS One 2010, 5, e9470.
138. Hyde, D.; Schulz, R.; Brooks, D.; Miller, E.; Ntziachristos, V. Performance dependence
of hybrid X-ray computed tomography/fluorescence molecular tomography on the optical
forward problem. J. Opt. Soc. Am. A 2009, 26, 919–923.
139. Tan, Y.; Jiang, H. Diffuse optical tomography guided quantitative fluorescence molecular
tomography. Appl. Opt. 2008, 47, 2011–2016.
140. Hervé, L.; Koenig, A.; Silva, A.D.; Berger, M.; Boutet, J.; Dinten, J.M.; Peltié, P.; Rizo,
P. Noncontact fluorescence diffuse optical tomography of heterogeneous media. Appl. Opt.
2007, 46, 4896–4906.
141. Milstein, A.B.; Oh, S.; Webb, K.J.; Bouman, C.A.; Zhang, Q.; Boas, D.A.; Millane, R.P.
Fluorescence optical diffusion tomography. Appl. Opt. 2003, 42, 3081–3094.
142. Lin, Y.; Yan, H.; Nalcioglu, O.; Gulsen, G. Quantitative fluorescence tomography with
functional and structural a priori information. Appl. Opt. 2009, 48, 1328–1336.
143. Lin, Y.; Gao, H.; Nalcioglu, O.; Gulsen, G. Fluorescence diffuse optical tomography with
functional and anatomical a priori information: feasibility study. Phys. Med. Biol. 2007,
52, 5569–5585.
144. Li, D.; Wang, W.; Wu, Q.; Ke, S.; Houston, J.; Sevick-Muraca, E.; Dong, L.; Chow, D.;
Charnsangavej, C.; Gelovani, J.G. Dual optical and nuclear imaging in human melanoma
xenografts using a single targeted imaging probe. Nucl. Med. Biol. 2006, 33, 349–358.
145. Edwards, W.B.; Akers, W.J.; Ye, Y.; Cheney, P.P.; Bloch, S.; Xu, B.; Laforest, R.; Achilefu,
S. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence,
gamma scintigraphy and SPECT methods using a cyclic RGD peptide labeled with a near
infrared fluorescent dye and a radionuclide. Mol. Imaging 2009, 8, 101–110.
Pharmaceutics 2011, 3 273
146. Lee, H.; Akers, W.J.; Cheney, P.P.; Edwards, W.B.; Liang, K.; Culver, J.P.; Achilefu, S.
Complementary optical and nuclear imaging of caspase-3 activity using combined activatable
and radio-labeled multimodality molecular probe. J. Biomed. Opt. Lett. 2009, 14, 040507.
147. Josephson, L.; Kircher, M.F.; Mahmood, U.; Tang, Y.; Weissleder, R. Near-infrared
fluorescencent nanoparticles as combined MR/optical imaging probes. Bioconjugate Chem.
2002, 13, 554–560.
148. Shan, L.; Wang, S.; Sridhar, R.; Bhujwalla, Z.M.; Wang, P.C. Dual probe with fluorescent
and magnetic properties for imaging solid tumor xenografts. Mol. Imaging 2007, 6, 85–95.
149. Ray, P.; Wu, A.M.; Gambhir, S.S. Optical bioluminescence and positron emission
tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice.
Cancer Res. 2003, 63, 1160–1165.
150. Cai, W.; Chen, K.; Gambhir, S.S.; Chen, X. Dual-function probe for PET and near-infrared
fluorescence imaging of tumor vasculature. J. Nucl. Med. 2007, 48, 1862–1870.
151. Ducongé, F.; Pons, T.; Pestourie, C.; Hérin, L.; Thézé, B.; Gombert, K.; Mahler, B.; Hinnen,
F.; Dollé, B.K.F.; Dubertret, B.; Tavitian, B. Fluorine-18-labeled phospholipid quantum
dot micelles for in vivo multimodal imaging from whole body to cellular scales. Bioconjugate
Chem. 2008, 19, 1921–1926.
152. Luker, G.D.; Sharma, V.; Pica, C.M.; Dahlheimer, J.L.; Li, W.; Ochesky, J.; Ryan, C.E.;
Piwnica-Worms, H.; Piwnica-Worms, D. Noninvasive imaging of protein-protein interactions
in living animals. Proc. Natl. Acad. Sci. USA 2002, 99, 6961–6966.
153. Ponomarev, V.; Doubrovin, M.; Sereganova, I.; Vider, J.; Shavrin, A.; Beresten, T.; Ivanova,
A.; Ageyeva, L.; Tourkova, V.; Balatoni, J.; Bornmann, W.; Blasberg, R.; Tjuvajev, R.G. A
novel triple-modality reporter gene for whole-body fluorescent bioluminescent and nuclear
noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 740–751.
154. Ray, P.; De, A.; Min, J.J.; Tsien, R.Y.; Gambhir, S.S. Imaging tri-fusion multimodality
reporter gene expression in living subjects. Cancer 2004, 64, 1323–1330.
155. Blasberg, R.G. In vivo molecular-genetic imaging: multi-modality nuclear and optical
combinations. Nucl. Med. Biol. 2003, 30, 879–888.
156. Becker, A.; Hassenius, C.; Licha, K.; Ebert, B.; Sukowski, U.; Semmler, W.; Wiedmann, B.;
Grötzinger, C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent
ligands. Nat. Biotechnol. 2001, 19, 327–331.
157. Birchler, M.; Neri, G.; Tarli, L.; Halin, C.; Viti, F.; Neri, D. Infrared photodetection for
the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J.
Immunol. Methods 1999, 231, 239–248.
158. Rudin, M.; Rausch, M.; Stoeckli, M. Molecular imaging in drug discovery and development:
potential and limitations of nonnuclear methods. Mol. Imaging Biol. 2005, 7, 5–13.
159. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergström,
M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; Ausén, B.; Debnath, M.L.; Barletta, J.;
Price, J.C.; Sandell, J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C.A.;
Langström, B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B.
Ann. Neurol. 2004, 55, 306–319.
Pharmaceutics 2011, 3 274
160. Garofalakis, A.; Zacharakis, G.; Meyer, H.; Economou, E.N.; Mamalaki, C.; Papamatheakis,
J.; Kioussis, D.; Ntziachristos, V.; Ripoll, J. Three-dimensional in vivo imaging of
green fluorescent protein-expressing T cells in mice with noncontact fluorescence molecular
tomography. Mol. Imaging 2007, 6, 96–107.
161. Kim, S.; Lim, Y.T.; Soltesz, E.G.; Grand, A.M.D.; Lee, J.; Nakayama, A.; Parker, J.A.;
Mihaljevic, T.; Laurence, R.G.; Dor, D.M.; Cohn, L.H.; Bawendi, M.G.; Frangioni, J.V.
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat.
Biotechnol. 2004, 22, 93–97.
162. Kozloff, K.M.; Quinti, L.; Patntirapong, S.; Hauschka, P.V.; Tung, C.H.; Weissleder, R.;
Mahmood, U. Non-invasive optical detection of cathepsin K-mediated fluorescence reveals
osteoclast activity in vitro and in vivo. Bone 2009, 44, 190–198.
163. Weissleder, R.; Ntziachristos, V. Shedding light onto live molecular targets. Nat. Med.
2003, 9, 123–128.
164. Bouchard, M.B.; MacLaurin, S.A.; Dwyer, P.J.; Mansfield, J.; Levenson, R.; Krucker, T.
Technical considerations in longitudinal multispectral small animal molecular imaging. J.
Biomed. Opt. 2007, 12, 051601.
165. Shu, X.; Wang, L.; Colip, L.; Kallio, K.; Remington, S.J. Unique interactions between
the chromophore and glutamate 16 lead to far-red emission in a red fluorescence protein.
Protein Sci. 2009, 18, 460–466.
166. Intes, X.; Ripoll, J.; Chen, Y.; Nioka, S.; Yodh, A.G.; Chance, B. In vivo continuous-wave
optical breast imaging enhanced with indocyanine green. Med. Phys. 2003, 30, 1039–1047.
167. Owen-Reece, H.; Smith, M.; Elwell, C.E.; Goldstone, J.C. Near infrared spectroscopy. Br.
J. Anaesth. 1999, 82, 418–426.
168. Villringer, A.; Planck, J.; Hock, C.; Schleinkofer, L.; Dirnagl, U. Near infrared spectroscopy
(NIRS): A new tool to study hemodynamic changes during activation of brain function in
human adults. Neurosci. Lett. 1993, 154, 101–104.
169. Custo, A.; Boas, D.A.; Tsuzuki, D.; Dan, I.; Mesquita, R.; Fischl, B.; Grimson, W.E.L.;
Wells, M., III. Anatomical atlas-guided diffuse optical tomography of brain activation.
Neuroimage 2010, 49, 561–567.
170. Ntziachristos, V.; Ripoll, J.; Weissleder, R. Would near-infrared fluorescence signals
propagate through large human organs for clinical studies? Opt. Lett. 2002, 27, 333–335.
c© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/.)
